



Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox

Review

Protective effect of curcumin against heavy metals-induced liver damage

W.R. Ramsés García-Niño, José Pedraza-Chaverri*

Department of Biology, Faculty of Chemistry, National Autonomous University of Mexico (UNAM), University City, 04510 D.F., Mexico

ARTICLE INFO

Article history:
Received 10 February 2014
Accepted 8 April 2014
Available online xxx

Keywords:
Hepatoprotective
Curcumin
Nrf2
Heavy metals
Oxidative stress
Mitochondrial dysfunction

ABSTRACT

Occupational or environmental exposures to heavy metals produce several adverse health effects. The common mechanism determining their toxicity and carcinogenicity is the generation of oxidative stress that leads to hepatic damage. In addition, oxidative stress induced by metal exposure leads to the activation of the nuclear factor (erythroid-derived 2)-like 2/Kelch-like ECH-associated protein 1/antioxidant response elements (Nrf2/Keap1/ARE) pathway. Since antioxidant and chelating agents are generally used for the treatment of heavy metals poisoning, this review is focused on the protective role of curcumin against heavy metals liver injury. Curcumin has shown, in clinical and preclinical studies, numerous biological activities including therapeutic efficacy against various human diseases and anti-hepatotoxic effects against environmental or occupational toxins. Curcumin reduces the hepatotoxicity induced by arsenic, cadmium, chromium, copper, lead and mercury, prevents histological injury, lipid peroxidation and glutathione (GSH) depletion, maintains the liver antioxidant enzyme status and protects against mitochondrial dysfunction. The preventive effect of curcumin on the noxious effects induced by heavy metals has been attributed to its scavenging and chelating properties, and/or to the ability to induce the Nrf2/Keap1/ARE pathway. However, additional research is needed in order to propose curcumin as a potential protective agent against liver damage induced by heavy metals.

© 2014 Published by Elsevier Ltd.

1. Introduction

Heavy metals are commonly defined as those metallic elements with high atomic weight such as arsenic (As), cadmium (Cd), chromium (Cr), copper (Cu), lead (Pb) and mercury (Hg) that may damage living organisms at low concentrations and that tend to accumulate in the food chain (IUPAC, 2002; Stummann et al., 2008). They enter to the human body by ingestion, inhalation or through the skin and their presence may cause serious toxicity (Jarup, 2003; Alissa and Ferns, 2011). Sources of exposure to these metals include occupational exposure and environmental contamination from industrial production with poor emission and disposal practices (Ahalya et al., 2003; CDC, 2009; Nobuntou et al., 2010; Martinez-Zamudio and Ha, 2011). The principal metal emission sources come from the following industries: petrochemical, extractive, metallurgic (foundry and metallurgy), mechanic (galvanic processes, painting), chemical (paints, plastic materials) and ceramic (Ziemacki et al., 1989). Exposure to compounds containing heavy metals is known to be toxic, mutagenic, teratogenic

and carcinogenic to human beings and diverse animals (Fig. 1) (Jomova and Valko, 2011).

Toxic manifestations of these metals are attributed primarily to oxidative stress (Flora et al., 2008). Oxidative stress is defined as an imbalance between production of free radicals and reactive metabolites, so-called oxidants, and their elimination by antioxidant systems. This imbalance leads to damage of important biomolecules and organs with potential impact on the whole organism (Duracková, 2010). The associated DNA, protein, and lipid damage may underlie liver diseases as a key pathophysiological force. The above may also be related to chronic liver injury, hepatic inflammation, fibrosis and to hepatocellular carcinoma (Tanikawa and Torimura, 2006; Vera-Ramirez et al., 2013). The liver is an important organ to be considered when the effects of pollutants are investigated, since this organ plays a central role in the metabolism and detoxification of biological substances. Also, most of the substances absorbed by the intestine passes first through the liver where toxins and heavy metals may accumulate (Saïdi et al., 2013).

Chromium and copper undergo redox-cycling reactions, while the primary route for the toxicity of arsenic, cadmium, lead and mercury is the depletion of glutathione (GSH) and bonding to sulfhydryl groups of proteins. But the unifying factor in determining toxicity and carcinogenicity for all these metals is the generation of reactive oxygen species (ROS) such as the hydroxyl radical

* Corresponding author. Address: Faculty of Chemistry, Department of Biology, Laboratory 209, Building F, National Autonomous University of Mexico (UNAM), University City, 04510, D.F., Mexico. Tel./fax: +52 55 5622 3878.

E-mail address: pedraza@unam.mx (J. Pedraza-Chaverri).




Fig. 1. Main organs and systems affected by environmental or occupational exposure to heavy metals.

(HO[•]), superoxide radical (O₂^{•-}) or hydrogen peroxide (H₂O₂). The excessive ROS generation overwhelms the cell's capacity to maintain a reduced state (Ercal et al., 2001; Valko et al., 2005, 2006). Oxidative stress induced by metal exposure leads to the activation of the nuclear factor (erythroid-derived 2)-like 2/Kelch-like ECH-associated protein 1/antioxidant response elements (Nrf2/Keap1/ARE) pathway (Rubio et al., 2010), through the activation of numerous transducers such as mitogen-activated protein kinases (MAPK, ERK, p38), protein kinase C (PKC), and phosphatidylinositol 3 kinase (PI3K) which phosphorylate both Nrf2 and Keap1 (Kang et al., 2000; Yu et al., 2000; Kong et al., 2001; Huang et al., 2002). Also, reactive electrophiles directly attack the sulfhydryl-rich Keap1 protein, leading to conformational changes in their structure (Dinkova-Kostova et al., 2002). The cumulative impact of these events is the stabilization and activation of Nrf2 and transcriptional upregulation of antioxidant genes protecting cells from heavy metal toxicity and carcinogenesis from ROS and electrophiles (Kaspar et al., 2009; Kensler et al., 2007; Park and Seo, 2011; Simmons et al., 2011; Lau et al., 2013).

Hence application of an external source of antioxidants may offer some protection against oxidative stress. The term antioxidant refers to a wide spectrum of compounds, which are able to donate electrons and neutralize free radicals, resulting in the prevention of cell injuries (Lobo et al., 2010; Saeidnia and Abdollahi, 2013). In consequence, the search for effective, nontoxic, natural compounds with antioxidant activity has been intensified in recent years (Pérez-De la Cruz et al., 2006; Tapia et al., 2012; Negrette-Guzmán et al., 2013). In particular, curcumin (a dietary spice isolated from *Curcuma longa*) has become one of the most cited antioxidants due to the multitude of beneficial health effects that have been studied and established by the scientific community (Kumar and Maliakel, 2007). However, there is little information about the protective effects of curcumin against noxious effects caused by exposure to heavy metals in murine models, including those related to hepatic damage. Thus, the purpose of this paper is to review scientific evidence regarding oxidative stress, Nrf2, and hepatotoxicity induced by heavy metals, as well as the hepatoprotective effects of curcumin.

2. Curcumin

Curcumin or diferuloylmethane (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-dione) is a hydrophobic polyphenol compound naturally concentrated in the rhizome of the herb *Curcuma longa*, commonly known as turmeric (Altenburg et al., 2011). Traditionally, turmeric has been used in therapeutic preparations against biliary disorders, anorexia, coryza, herpes zoster, acne, cough, urinary tract diseases, diabetic wounds, hepatic disorder, rheumatism and sinusitis (Ammon and Wahl, 1991; Chainani-Wu, 2003; Chattopadhyay et al., 2004). At present, turmeric is used as a dietary spice, and by the food industry as additive, flavoring, preservative and as coloring agent in foods and textiles (FAO, 2004; Aggarwal et al., 2007; Basnet and Skalko-Basnet, 2011). Curcumin is a major component of turmeric and it has been shown to exhibit several activities including antioxidant (Iqbal et al., 2003; Surh, 2003; Dairam et al., 2008; Al-Jassabi et al., 2012), antimicrobial (Çikrikçi et al., 2008; Tajbakhsh et al., 2008), anti-inflammatory (Jurenka, 2009; Bereswill et al., 2010), antiviral (Barthelemy et al., 1998; Kutluay et al., 2008) and anticarcinogenic (Aggarwal et al., 2003, 2006; Wang et al., 2009; Youns et al., 2010; Das and Vinayak, 2012; Huang et al., 2013).

Curcumin and turmeric products have been characterized as safe by the Food and Drug Administration (FDA) in the USA, the Natural Health Products Directorate of Canada and the Joint FAO/WHO Expert Committee on Food Additives of the Food and Agriculture Organization/World Health Organization (NCI, 1996). Over 2400 metric tons of turmeric are imported into the USA (Sharma et al., 2005). The average intake of turmeric in the Indian diet is approximately 2–2.5 g for a 60 kg individual, which corresponds to a daily intake of approximately 60–100 mg of curcumin (Shah et al., 1999; Lao et al., 2006; Tayyem et al., 2006). In addition, curcumin has entered scientific clinical trials in the phase I, II and III levels for its therapeutic efficacy, even at doses as high as 12 g/day during 3 months (Cheng et al., 2001; Hsu and Cheng, 2007; NIH, 2007; Dhillon et al., 2008). However, curcumin exhibits poor bioavailability and the hydrophobic nature of curcumin is one of the main reasons for this poor water-solubility/suspension capacity (Anand et al., 2008; Kidd, 2009). To improve the solubility, bioavailability and bioactivity of curcumin, numerous approaches have been undertaken. These include (1) curcumin analogues: natural analogues from turmeric such as demethoxycurcumin, bisdemethoxycurcumin or tetrahydrocurcumin (Gryniewicz and Ślifirski, 2012; Lin et al., 2012; Bhullar et al., 2013), natural analogues occurring in nature, like cassumunins or dehydrozygerone (Nagano et al., 1997; Yogosawa et al., 2012) and synthetic analogues (Al-Hujaily et al., 2011; Chen et al., 2011; Yadav et al., 2012b), and (2) curcumin formulations: adjuvants (Sehgal et al., 2011; Banji et al., 2013), nanoparticles (Gangwar et al., 2012; Liu et al., 2012), liposomes (Taylor et al., 2011; Dhule et al., 2012), micelles (Gong et al., 2013; Liu et al., 2013a,b) and phospholipid complexes (Lin et al., 2009).

2.1. Therapeutic potential

Despite its low bioavailability, numerous clinical studies have suggested that curcumin has therapeutic efficacy against various human diseases (Gupta et al., 2013), including cancer (Garcea et al., 2004, 2005), diabetes (Balasubramanyam et al., 2003), Alzheimer's disease (Ringman et al., 2012), familial adenomatous polyposis (Cruz-Correa et al., 2006), inflammatory bowel disease (Holt et al., 2005), rheumatoid arthritis (Deodhar et al., 1980; Chandran and Goel, 2012), hypercholesterolemia (Soni and Kuttan, 1992), liver injury (Kim et al., 2013), atopic asthma (Kim et al., 2011), psoriasis (Kurd et al., 2008), osteoarthritis (Belcaro et al., 2010), neurological diseases (Sanmukhani et al., 2013),

189 chronic anterior uveitis (Lal et al., 1999; Allegri et al., 2010), human
190 immunodeficiency virus infection (James, 1994) and cystic fibrosis
191 (Henke, 2008). Enhancing curcumin's bioavailability in the near
192 future is will enable this promising natural product to be investi-
193 gated as a therapeutic agent for treatment of human disease
194 (Anand et al., 2007).

195 2.2. Antioxidant properties

196 Curcumin is a bis- α,β -unsaturated β -diketone and the β -diketo
197 moiety undergoes keto-enol tautomerism (Fig. 2). Under acidic and
198 neutral conditions, the bis-keto form predominates, whereas the
199 enol form is found above pH 8 (Wang et al., 1997; Jovanovic
200 et al., 1999). The enol form makes an ideal chelator of positively
201 charged metals (Fig. 3), which are often found in the active sites
202 of target proteins (Baum and Ng, 2004). Curcumin chelating
203 potential of the type 1:1 and 1:2 have been reported for several
204 metal cations (Gupta et al., 2011). The presence of the phenolic,
205 β -diketone, as well as the methoxy groups contribute to the free-
206 radical-scavenging activity of curcumin (Esatbeyoglu et al., 2012).
207 Curcumin has demonstrated scavenging activity against a variety
208 of ROS, including O_2^- , HO^\cdot , peroxy radical (ROO^\cdot), nitrogen dioxide
209 radical (NO_2^\cdot), 1,1-diphenyl-2-picryl-hydrazyl free radical (DPPH),
210 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS⁺) and
211 Q5 N,N -dimethyl-*p*-phenylenediamine dihydrochloride (DMPD⁺) radical
212 (Reddy and Lokesh, 1994; Fujisawa et al., 2004; Ak and Gülcin,
213 2008; Trujillo et al., 2013). On the other hand, curcumin may pro-
214 tect cells from oxidative stress indirectly by inducing Nrf2 (Fig. 4)
215 (Tapia et al., 2012, 2013; Correa et al., 2013; González-Reyes et al.,

216 2013). Nrf2 belongs to the CNC (cap 'n' collar) family of b-Zip tran-
217 scription factors, together with p45 NF-E2, Nrf1 and Nrf3, and acts
218 through the formation of a heterodimer with one of the small Maf
219 proteins (Motohashi et al., 2002; Motohashi and Yamamoto, 2004).
220 Nrf2 is a redox-sensitive transcription factor which, under basal
221 conditions, is bound to its repressor Keap1 in the cytoplasm
222 (Copple et al., 2008; Singh et al., 2010; Uruno and Motohashi,
223 2011; Buelna-Chontal and Zazueta, 2013). Keap1 serves as an
224 adaptor protein between Nrf2 and the Cullin3-based E3-ligase
225 ubiquitylation complex, with its N-terminal BTB leading to ubiqui-
226 tylation of Nrf2 and subsequent degradation by the 26S protea-
227 some (Cullinan et al., 2004; Sinha et al., 2013). Curcumin
228 contains two Michael reaction acceptor functionalities in its mole-
229 cule that can modify the cysteine residues of Keap1 and promote a
230 conformational change in the Nrf2-Keap1 complex by Michael
231 addition to the thiols in Keap1 (Dinkova-Kostova et al., 2001;
232 Balogun et al., 2003), thereby releasing Nrf2 and allowing it to
233 translocate into the nucleus and bind as a heterodimer to ARE in
234 DNA to initiate target gene expression and increase the expression
235 of phase II enzymes (Dinkova-Kostova and Talalay, 1999, 2008;
236 Hong et al., 2005). Dinkova-Kostova and Talalay, 1999 identified
237 that the presence of keto-enol functionality and the aromatic ring
238 system must be present to provide Nrf2 inducer activity to curcu-
239 min. In this way, curcumin upregulates genes that contain AREs
240 in their promoters, including superoxide dismutase (SOD), catalase
241 (CAT) (Shukla et al., 2003), glutathione peroxidase (GPx) (Piper
242 et al., 1998), glutathione reductase (GR), glutathione-S-transferase
243 (GST) (Oetari et al., 1996), heme oxygenase 1 (HO-1) (Balogun
244 et al., 2003), NADPH:quinone oxidoreductase 1 (NQO1), glutamate




Fig. 2. Curcumin keto-enol tautomerism. The presence of the phenolic, β -diketone, as well as the methoxy groups contributes to the free-radical-scavenging activity of curcumin. The enol form makes an ideal chelator of positively charged metals. While the presence of keto-enol functionality and the aromatic ring system must be present to provide Nrf2 inducer activity to curcumin.




Fig. 3. Curcumin chelating potential for metallic and semi metallic cations.




Fig. 4. General scheme for the induction of gene expression through Keap1/Nrf2/ARE pathway. Nrf2 is a redox-sensitive transcription factor which, under basal conditions, is bound to its repressor Keap1 in the cytoplasm. Keap1 serves as an adaptor protein between Nrf2 and the Cul3 complex, leading to ubiquitylation of Nrf2 and subsequent degradation by the 26S proteasome. Oxidative stress induced by heavy metals exposure leads to the activation of the Nrf2/Keap1/ARE pathway. Protective effects of curcumin were attributed to its ability to scavenge free radicals, to act as an chelating agent and/or its capacity to induce detoxifying enzymes by the up regulation of Keap1/Nrf2/ARE pathway. Reactive oxygen species (ROS), Kelch-like ECH-associated protein 1 (Keap1); nuclear factor (erythroid-derived 2)-like 2 (Nrf2); antioxidant responsive element (ARE); cullin-3 (Cul3); NADPH: quinone oxidoreductase 1 (NQO1); glutathione-S-transferase (GST); heme oxygenase-1 (HO-1).

cysteine ligase catalytic (GCLC) and regulatory (GCLM) subunits (Zhao et al., 2013) and aldose reductase (Kang et al., 2008).

Curcumin natural analogues from turmeric, other naturally-occurring analogues, synthetic analogues, and curcumin formulations exhibit different antioxidant activities in several in vitro and in vivo models (Anand et al., 2008). Curcumin was more potent than demethoxycurcumin and bisdemethoxycurcumin (Ahsan et al., 1999; Jeong et al., 2006). However tetrahydrocurcumin, one of the major metabolites of curcumin, exhibits greater antioxidant potential than curcumin in most models (Somparn et al., 2007; Wongeakin et al., 2009). On the other hand, the information about the antioxidant potential of curcumin in comparison with other naturally-occurring analogues is scarce; as a result, it is necessary to perform comparative studies about it. In this respect, caffeic acid, ferulic acid and capsaicin have shown a higher relative antioxidant potency than curcumin, but not eugenol or dehydrozingerone in some models (Sharma, 1976; Joe and Lokesh, 1994; Rajakumar and Rao, 1994), indicating that an ortho-methoxylated phenolic chromophore is necessary for antioxidant activ-

ity. Finally, molecular design and synthesis of synthetic curcumin analogues have improved the antioxidant activity in contrast with curcumin in many experimental conditions (Wright, 2002; Selvam et al., 2005; Youssef et al., 2007).

2.3. Anti-hepatotoxic properties

The anti-hepatotoxic effects of curcumin against environmental or occupational toxins are well documented, and they have been attributed to its intrinsic antioxidant, anti-inflammatory, anti-cholestatic, anti-fibrogenic and anti-carcinogenic properties. Thus, curcumin has shown to protect the liver against injury and fibrogenesis by suppressing hepatic inflammation, attenuating hepatic oxidative stress (Mathuria and Verma, 2007), increasing expression of the xenobiotic detoxifying enzymes (Iqbal et al., 2003; Hemeida and Mohafez, 2008; Farghaly and Hussein, 2010), inhibiting hepatic stellate cells activation (Zheng et al., 2007; Priya and Sudhakaran, 2008) and supporting the mitochondrial function (Subudhi et al., 2008). In addition, curcumin has shown

Table 1
Curcumin hepatoprotective properties.

| Properties | Outcome | References |
|------------------------|--|---|
| Antihepatotoxic | ↓ Structural alterations ↓ Activities of ALT, AST, ALP, ACP, LDH and γ -GT ↓ Total bilirubin ↑ Serum proteins | Kaur et al. (2006), Dattani et al. (2010), Nayak and Sashidhar (2010), Naik et al. (2011) |
| Antioxidant | ↓ Lipid and protein oxidation ↓ ROS y RNS ↑ Expression and activities of SOD, CAT, GPx, GR, GST, HO-1, NQO1 and GCL ↑ GSH ↑ Induction of Nrf2 ↑ Activity of cytochrome P450 ↑ Mitochondrial function ↑ Activities of SDH and ATPase | Sugiyama et al. (2006), Wei et al. (2006), Farombi et al. (2008); Srinivasan et al. (2008), Ramirez-Tortosa et al. (2009), Bao et al. (2010), El-Agamy (2010), Yousef et al. (2010), Guangwei et al. (2010), Subudhi and Chainy (2010), Tokaç et al. (2013) |
| Anti-cholestatic | ↑ Serum cholesterol ↑ Bile acids ↑ Direct and/or total bilirubin | Ahmed and Manna (2004), Said and El-Agamy (2009) |
| Antifibrotic | ↓ Activation of HSC ↑ Activation of PPAR- γ ↓ Expression of PDGF, EGF, TGF- β and their receptors ↓ Collagen α 1(I), fibronectin, TIMP-1 and α -SMA | Fu et al. (2008), Lin and Chen (2008) Pinlaor et al. (2010) Vizzutti et al. (2010) |
| Anti-inflammatory | ↓ Activation of NF- κ B ↓ Expression of TNF- α , IFN- γ , IL-1 β , IL-6, IL-12, IFN- γ , MCP-1 and ICAM-1 ↓ Expression of COX-2, iNOS ↓ Expression of TLR2 and TLR4 | Nanji et al. (2003), Leclercq et al. (2004), Reyes-Gordillo et al. (2007), Tu et al. (2012) |
| Antihepatocarcinogenic | ↑ Apoptosis ↓ Expression of p53 and p21 ^{ras} ↓ Expression of PCNA, p34 ^{cdc2} and cyclin E | Chuang et al. (2000a,b), Cao et al. (2007), Qian et al. (2011), Wang et al. (2011) |

Alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP); acid phosphatase (ACP); lactate dehydrogenase (LDH); γ -glutamyl transferase (γ -GT); reactive oxygen species (ROS); reactive nitrogen species (RNS); superoxide dismutase (SOD); catalase (CAT); glutathione peroxidase (GPx); glutathione reductase (GR); glutathione-S-transferase (GST); heme oxygenase-1 (HO-1); NADPH:quinone oxidoreductase 1 (NQO1); glutamate-cysteine ligase (GCL); glutathione (GSH); nuclear factor (erythroid-derived 2)-like 2 (Nrf2); succinate dehydrogenase (SDH); adenosine triphosphatase (ATPase); hepatic stellate cells (HSC); peroxisome proliferator-activated receptor- γ (PPAR- γ); platelet-derived growth factor (PDGF); epidermal growth factor (EGF); transforming growth factor- β (TGF- β); tissue inhibitor of metalloproteinase-1 (TIMP-1); α -smooth muscle actin (α -SMA); nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B); tumor necrosis factor- α (TNF- α); interleukin-1 β , -6, -12 (IL-1 β , IL-6, IL-12); interferon- γ (IFN- γ); monocyte chemoattractant protein (MCP-1); intercellular adhesion molecule-1 (ICAM-1); cyclooxygenase-2 (COX-2); inducible nitric oxiden synthase (iNOS); Toll like receptor-2, -4 (TLR2, TLR4); proliferating cell nuclear antigen (PCNA).

281 protective effects against liver injury by upregulating the Keap1/
282 Nrf2/ARE pathway (Garg et al., 2008). These properties make cur-
283 curmin a potential protective agent against heavy metal-induced
284 liver injury (Table 1).

285 3. Arsenic hepatotoxicity

286 Epidemiological studies have clearly indicated an association
287 between chronic arsenic exposure and abnormal liver function,
288 hepatomegaly, hepatoportal sclerosis, ascites, liver fibrosis and
289 cirrhosis (Nevens et al., 1990; Li et al., 2006; Flora et al., 2007;
290 Liu and Waalkes, 2008), from exposure to arsenic in the drinking
291 water (Santra et al., 1999; Guha Mazumder, 2005; Das et al.,
292 2012), environmental exposure to arsenic through burning high-
293 arsenic coal in interior stoves (Lu et al., 2001; Liu et al., 2002), or
294 when it is used as a therapeutic agent in the treatment of leukemia
295 (Hao et al., 2013; Wang et al., 2013a,b). The mechanisms by which
296 arsenic causes hepatotoxicity are not fully elucidated, however,
297 emerging evidence supports the role of oxidative stress and inflam-
298 mation in the pathogenesis of arsenic-induced organ damage
299 (Dong, 2002; Fouad et al., 2012). It has been shown that arsenite
300 and other arsenicals induce in liver the following alterations:
301 Q6 hepatocellular damage, hepatomegaly, oxidative stress (Guha
302 Mazumder, 2005; Nandi et al., 2005; Bashir et al., 2006; Xu et al.,
303 2013a,b), oxidative stress in liver mitochondria, inappropriate
304 mitochondrial permeability transition (Santra et al., 2007;
305 Hosseini et al., 2013), apoptosis (Zhang et al., 2013), hepatic stea-
306 tosis, inflammation, necrosis and fibrosis associated with hepatic

stellate cells (HSCs), NADPH oxidase and TGF- β /SMAD activation
(Ghatak et al., 2011; Pan et al., 2011) and liver carcinogenesis
(Liu et al., 2006; Waalkes et al., 2006; Xie et al., 2007).

310 3.1. Mechanism of action and Nrf2 induction

311 Evidence of oxidative stress has been detected in almost all the
312 experimental conditions of arsenic toxicity (Das et al., 2005;
313 Jomova et al., 2011). Arsenic may cause an increase in production
314 of ROS such as O₂⁻, H₂O₂, ROO[•], singlet oxygen (¹O₂), nitric oxide
315 (NO[•]), dimethylarsinic peroxy radical [(CH₃)₂AsOO[•]] and the
316 dimethylarsinic radical [(CH₃)₂As[•]] (Valko et al., 2006). It has been
317 suggested that mitochondria are the main target for arsenic-
318 containing compounds with a deflection of electrons from the
319 respiratory chain to generate ROS, inhibitory effects on cellular res-
320 piration, disruption of oxidative phosphorylation and concomitant
321 decrease in the cellular levels of adenosine triphosphate (ATP)
322 (Fluharty and Sanadi, 1962; Chen et al., 1986). ROS might also be
323 produced by cytosolic enzymes with peroxidase activity or during
324 the oxidation of As(III) to As(V) (Henkler et al., 2010). ROS produc-
325 tion by arsenic may result in an attack, not only against antioxidant
326 defenses and DNA, but also against membrane phospholipids,
327 which are very sensitive to oxidation, producing ROO[•] and then
328 malondialdehyde (MDA) (Escobar et al., 2010). On the other hand,
329 arsenic may also generate its toxic effects via bonding to sulfhydryl
330 groups of proteins and depletion of GSH (Hossain et al., 2000;
331 Jomova and Valko, 2011).

332 Nrf2 activation by arsenic induced-cell damage has been
333 reported in osteoblasts (Aono et al., 2003), human keratinocytes

(Pi et al., 2003; Endo et al., 2008; Zhao et al., 2011), embryonic fibroblasts (He et al., 2006), human breast adenocarcinoma and human urothelial cells (Wang et al., 2008), pancreatic β -cells (Yang et al., 2012), endothelial cells (Wang et al., 2012) and skin lesions in people exposed to inorganic arsenic-contaminated water (Cordova et al., 2013). Aono et al. (2003) reported for the first time that inorganic arsenic activates the transcription factor Nrf2 and Pi et al. (2003) indicated that H_2O_2 is the mediator of arsenic-induced nuclear Nrf2 accumulation. On the other hand, Jiang et al. (2009) presented evidence that Nrf2 protects against liver and bladder injury in mice treated with arsenic ameliorating the pathological changes, DNA hypomethylation, oxidative DNA damage and apoptotic cell death. Abiko et al. (2010) observed in human hepatocarcinoma cells (HepG2) a reduction of arsenic-induced cytotoxicity through Nrf2/HO-1 signaling. Li et al. (2011) and Liu et al. (2013a,b) demonstrated that sodium arsenite exposure in Chang human hepatocytes increased Nrf2 protein levels, HO-1, NQO1 and GSH, as an adaptive cell defense mechanism against hepatotoxicity. Recently, Anwar-Mohamed et al. (2013) showed that methylated pentavalent arsenic metabolites are bifunctional inducers as they increase cytochrome P450 1A1 (CYP1A1) through activating the aryl hydrocarbon receptor (AhR) and NQO1 through activating the Nrf2/Keap1/ARE signaling pathway in HepG2 cells.

3.2. Curcumin hepatoprotection

Curcumin has shown beneficial effects in clinical trials in patients with arsenic-induced genotoxicity (Biswas et al., 2010b; Roy et al., 2011) and arsenic-induced Bowen's disease (Cheng et al., 2001). Also, in studies in rodents and in in vitro models, curcumin has shown protective effect against arsenic-induced genotoxicity (Mukherjee et al., 2007; Roy et al., 2008; Biswas et al., 2010a; Tiwari and Rao, 2010), angiogenesis (Pantazis et al., 2010), skin disorders (Zhao et al., 2013), reproductive toxicity (Reddy et al., 2012; Khan et al., 2013), neurotoxicity (Yadav et al., 2009, 2010, 2011), immunotoxicity (Khan et al., 2012; Sankar et al., 2013c), nephrotoxicity (Sankar et al., 2013b) and hepatotoxicity. Yousef et al. (2008) and El-Demerdash et al. (2009) treated rats with sodium arsenite (5 mg/kg) and curcumin (15 mg/kg) and they found that curcumin ameliorates arsenic-induced liver damage preventing hepatomegaly and loss of body weight. Curcumin treatment also preserved the structural integrity of the hepatocellular membrane, prevented lipid peroxidation and the decrease in the content of GSH and total proteins and changes in the liver activity of the antioxidant enzymes GST, SOD and CAT. This protective effect of curcumin was attributed to its ability to scavenge free radicals (Ak and Gülcin, 2008), to induce detoxifying enzymes (Dinkova-Kostova and Talalay, 1999; Messarah et al., 2013) and to block thiol depletion (Donatus et al., 1990).

In contrast, Gao et al. (2013) demonstrated in female Kunming mice exposed to sodium arsenite (10, 50, 100 mg/L) in drinking water that the co-treatment with curcumin (200 mg/kg), reduced the arsenic-induced hepatic injuries by supporting arsenic methylation and accelerating its urinary excretion, as a detoxification process. Notably, these authors observed that treatment with curcumin antagonized arsenic-induced hepatic oxidative stress by the upregulation of Nrf2 and the induction of NQO1 and HO-1 proteins, two typically recognized Nrf2 downstream targets. Similarly, curcumin led to nuclear accumulation of Nrf2 protein and increased the expression of ARE regulated genes in keratinocytes (HaCaT) treated with sodium arsenite, augmenting the viability and survival of cells upregulating NQO1, HO-1, GCL, and GCLM genes expression (Zhao et al., 2013). Previously, Farombi et al. (2008) had found that liver protection by curcumin is mediated by Nrf2 activation.

In order to increase curcumin's bioavailability, Yadav et al. (2012a,b) prepared encapsulated curcumin chitosan nanoparticles (nanocurcumin) and they treated rats with sodium arsenite (2 mg/kg) plus curcumin (15 mg/kg) or nanocurcumin (1.5 and 15 mg/kg). Co-administration of curcumin or nanocurcumin ameliorated changes in hepatic oxidative stress parameters and re-established the activity of SOD and CAT. Remarkably, nanocurcumin (15 mg/kg) chelates arsenic more effectively than curcumin from blood, liver, brain and kidneys and retained its ability as an antioxidant. Nanocurcumin increases the efficacy and bioavailability of curcumin and reduces the dose required to exert protective effect against arsenic toxicity. Recently, Sankar et al. (2013a) described that nanoparticle-encapsulated curcumin in poly(lactic-co-glycolic acid) (PLGA) showed hepatoprotective effects against sodium arsenite-induced oxidative damage. Rats were treated with sodium arsenite (25 ppm) plus curcumin (100 mg/kg) or curcumin-nanoparticles (100 mg/kg). In this case, curcumin and nano-encapsulated curcumin protected against arsenic-induced hepatotoxicity by reducing lipid peroxidation, supporting GSH levels and SOD, CAT, GPx and GR activities. However, curcumin-nanoparticles showed higher protection than free curcumin. Sankar et al. (2013b) have demonstrated that curcumin-nanoparticles show immunomodulatory effects in arsenic-exposed rats.

On the other hand, Mathews et al. (2012) induced oxidative stress by treating rats with arsenic trioxide (4 mg/kg) and curcumin (15 mg/kg). In this model, curcumin prevents the arsenic trioxide-induced hepatic dysfunction and oxidative stress by maintaining the liver antioxidant enzyme status. Thus, curcumin protects against arsenic-induced hepatic damage scavenging free radicals, chelating arsenicals compounds or activating Nrf2/Keap1/ARE pathway.

4. Cadmium hepatotoxicity

The liver is critically damaged by acute or chronic exposure to cadmium (Souza et al., 1996; Yamano et al., 1999; Casalino et al., 2006). Acute cadmium exposure has been related to the elevation in the levels of serum liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (Kang et al., 2013), hepatic necroinflammation, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fibroplasias and liver-related mortality (Chang et al., 2012; Hyder et al., 2013). A critical determining factor in cadmium-induced liver injury is the hepatic concentration of metallothionein (MT) (Kuester et al., 2002). MT is a low molecular weight, cysteine-rich, intracellular protein with high affinity for both essential and non-essential metals (Park et al., 2001). MT forms a complex with cadmium and reduces its free concentration within the cell, thus reducing the hepatotoxic potential of cadmium (McKenna et al., 1996; Klaassen et al., 2009). As the binding capacity of MT becomes saturated, the increased availability of unbound cadmium initiates a series of events resulting in cell injury or death (Goering et al., 1993; Shaikh et al., 1999). Cadmium hepatotoxicity also involves the binding of Cd^{2+} to sulfhydryl groups on critical molecules, thiol group inactivation, oxidative stress (Bucio et al., 1995; Casalino et al., 2002), mitochondrial permeability transition (Li et al., 2003), mitochondrial dysfunction (Al-Nasser, 2000), mitochondrial fragmentation (Xu et al., 2013a,b) and apoptosis (Habeebu et al., 1998). Secondary injury from acute cadmium exposure occurs from the activation of Kupffer cells and neutrophil infiltration; pro-inflammatory cytokines and chemokines have also been implicated in the toxic process (Sauer et al., 1997; Rikans and Yamano, 2000).

4.1. Mechanism of action and Nrf2 induction

Cadmium competes with essential metals, that have well-defined homeostatic uptake and efflux pathways, for the same transport systems to enter into the cells, disrupting the intracellular balance of the essential metals and producing toxic effects (Souza et al., 1997; Ohrvik et al., 2007). Metals susceptible to the mimetic action of cadmium include calcium, zinc, magnesium and iron (Martelli et al., 2006). ROS are often implicated in cadmium-induced deleterious health effects and HO[•], O₂^{•-} and H₂O₂ have been detected *in vivo*, which are often accompanied by activation of redox sensitive transcription factors like nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), activating protein-1 (AP-1) and Nrf2, and alteration in the expression of ROS related genes (Patra et al., 2011; Wu et al., 2012). Thus, cadmium induces tissue injury through oxidative stress, increase in lipid peroxidation, alterations in the antioxidant defense system (Jurczuk et al., 2006; Thijssen et al., 2007), epigenetic changes in DNA expression, inhibition of heme synthesis, depletion of GSH and distortion of proteins due to cadmium binding to sulfhydryl groups (Bernhoft, 2013), disruption of calcium homeostasis (Leffler et al., 2000; Yuan et al., 2013), impairment of mitochondrial function (Chávez et al., 1985; Takaki et al., 2004; Cannino et al., 2009) and apoptosis (Kim et al., 2000).

Activation of Nrf2 by cadmium has been described in rat kidney cells (Chen and Shaikh, 2009), rat heart (Ferramola et al., 2011), mouse macrophages (Ishii et al., 2000) and mouse embryonic fibroblasts (He et al., 2008). Stewart et al. (2003) identified that treatment of mouse hepatoma (Hepa 1c1c7) cells with cadmium chloride increased the half-life of Nrf2 by delaying the rate of Nrf2 degradation. Wu et al. (2012) investigated the role of Nrf2 in cadmium-induced hepatotoxicity in a murine model. Nrf2-null mice, wild-type mice, Keap1-knockdown mice with enhanced Nrf2, and Keap1-hepatocyte knockout mice with maximum Nrf2 activation were treated with cadmium chloride. These authors found that Nrf2 activation prevents cadmium-induced oxidative stress and liver injury by inducing genes involved in antioxidant defense rather than genes that scavenge cadmium. Similarly, Casalino et al. (2006, 2007) showed that in the liver of acutely cadmium-intoxicated rats, the activation of the Nrf2 factor was significantly increased, as well as the ARE-mediated gene expression and activity of NQO1 and α-GST. This probably occurs through activating protein kinases that promote the phosphorylation of Nrf2, or by the interaction of heavy metals with sulfhydryl groups of Keap1 altering the structure of this inhibitor, removing the association between Nrf2 with Keap1 and consequently activating ARE-mediated gene expression.

4.2. Curcumin hepatoprotection

In several studies in rodents and *in vitro* models, curcumin has been shown to have the potential to protect against cadmium nephrotoxicity (Tarasub et al., 2011; Deevika et al., 2012), immunotoxicity (Pathak and Khandelwal, 2008; Alghasham et al., 2013), lung diseases (Rennolds et al., 2012), reproductive toxicity (Souza et al., 1996; Salama and El-Bahr, 2007; Oguzturk et al., 2012; Singh et al., 2012), neurotoxicity (Daniel et al., 2004), colon toxicity (Singh et al., 2011) and hepatotoxicity. In this context, Eybl et al. (2004) investigated the preventive effect of curcumin on cadmium-induced liver damage in rats and mice. Animals were treated with curcumin (50 mg/kg) and cadmium chloride (rats 25 μmol/kg and mice 30 μmol/kg). Curcumin ameliorated the cadmium-induced hepatic lipid peroxidation. However, curcumin treatment did not exert any change on GSH levels, probably because of the relatively low dose of the antioxidant and the short duration of treatment (3 days). Moreover, they evaluated

the trace element concentrations in the liver and their results suggested that curcumin could regulate the status of essential metals involved in cadmium toxicity, like zinc and iron. In a second study, Eybl et al. (2006b) examined the capacity of curcumin and manganese (Mn) complex of curcumin (Mn-curcumin) to protect against cadmium-induced oxidative damage. Manganese was incorporated in the curcumin structure in order to exert SOD activity and to potentiate the radical scavenging ability (Vajragupta et al., 2006). Mice were pre-treated with curcumin or Mn-curcumin (0.14 mmol/kg) and intoxicated with cadmium chloride (33 μmol/kg). Curcumin and Mn-curcumin effectively prevented the increase of hepatic lipid peroxidation and attenuated the cadmium-induced decrease in hepatic GSH levels. The activity of GPx or CAT in liver was unchanged in cadmium-treated mice. On the other hand, the authors did not find any differences in cadmium distribution in tissues; neither curcumin nor Mn-curcumin corrected the changes in the balance of essential elements caused by cadmium. They also demonstrated that incorporating manganese into the curcumin molecule does not potentiate the antioxidant action of curcumin. Later, Eybl et al. (2006a) designed a comparative study of natural antioxidants against cadmium-induced oxidative damage in mice. Animals were treated with cadmium chloride (7 mg/kg) and curcumin (50 mg/kg), resveratrol (20 mg/kg) or melatonin (12 mg/kg). All antioxidants prevented hepatic lipid peroxidation but only curcumin and melatonin ameliorated the decrease in GSH in cadmium-exposed mice. The antioxidants completely prevented the cadmium-induced decrease in hepatic GPx activity, and CAT activity was maintained only by resveratrol. The accumulation of cadmium was measured in liver, brain, kidneys and testes and was not affected by antioxidants pre-treatment. In this case, curcumin acts as a scavenger rather than as a chelating agent.

In 2008, Tarasub et al. treated rats with cadmium acetate (200 mg/kg) and co treated with curcumin (250 mg/kg). They found that curcumin was unable to prevent against cadmium-induced oxidative damage. But recently, Tarasub et al. (2012) have reported that curcumin (200 and 400 mg/kg) in combination with vitamin C (100 mg/kg) can prevent the cadmium-induced oxidative damage, MT expression and liver structural lesions at dose of 5 mg/kg. According to the authors, the combined treatment was more effective than with either antioxidant alone as a consequence of the antioxidant/anti-radical properties of curcumin and vitamin C. Thus, curcumin protects against cadmium-induced hepatic injury scavenging free radicals. Nevertheless, in these models it was not determined whether curcumin could act as an indirect antioxidant and activate the Nrf2/Keap1/ARE pathway and it remains to be determined if curcumin prevents the decreased activity of antioxidant enzymes and GSH by activating this pathway or by acting as a direct antioxidant. Daniel et al. (2004) demonstrated the chelating capacity of curcumin against cadmium in rat brain. So it is important to determine whether curcumin has the same activity in the liver.

5. Chromium hepatotoxicity

Several studies have demonstrated that liver is an organ capable of being injured by Cr(VI) (Wood et al., 1990) and histopathological changes such as parenchymatous degeneration, steatosis of hepatocytes and necrosis have been observed (Woźniak et al., 1991; Kurosaki et al., 1995; Acharya et al., 2001). Cr(VI) hepatotoxicity is associated with increased ROS levels (Wang et al., 2006; Patlolla et al., 2009), lipid peroxidation (Bagchi et al., 1995a, 1995b), DNA damage (Yuann et al., 1999), inhibition of DNA, RNA and protein synthesis (Gunaratnam and Grant, 2008), reduction of the activity of the antioxidant enzymes (Ueno et al., 1989;

Anand, 2005; Soudani et al., 2013), mitochondrial damage (Pourahmad et al., 2001, 2005) including impaired mitochondrial bioenergetics (Ryberg and Alexander, 1984; Fernandes et al., 2002), cell growth arrest (Xiao et al., 2012) and apoptosis (Kalayarasan et al., 2008).

5.1. Mechanism of action and Nrf2 induction

Cr(III) is poorly transported across membranes, while the chromate ion (CrO_4^{2-}), the dominant form of Cr(VI) in neutral, aqueous solutions and structurally similar to phosphate and sulfate, can be transported into cells by the anion carrier in cellular membranes (Alexander and Aaseth, 1995). Inside cells, Cr(VI) is reduced through reactive intermediates Cr(V), Cr(IV) and to the more stable Cr(III) by cellular reductases such as GSH, cysteine, ascorbic acid and riboflavin and NADPH-dependent flavoenzymes, cytochrome P450 reductases and the mitochondrial electron transport chain (Jannetto et al., 2001; Pourahmad and O'Brien, 2001; Ueno et al., 2001). The redox couples Cr(VI)/(V), Cr(V)/(IV), Cr(IV)/Cr(III) and Cr(III)/(II) have been shown to serve as cyclical electron donors in a Fenton-like reaction, which generates ROS such as O_2^- , H_2O_2 , OH \cdot , thiyl radicals and carbon-based radicals (Stoys and Bagchi, 1995; Liu and Shi, 2001), leading to genomic DNA damage (Henkler et al., 2010), oxidative deterioration of lipids and proteins (Kalahasthi et al., 2006; Myers et al., 2008, 2011), activation of NF- κ B and tumor suppressor protein p53 (Ye et al., 1999; Son et al., 2010), cell cycle arrest, tyrosine phosphorylation (Bagchi et al., 2001; Ding and Shi, 2002); mitochondrial damage (Ryberg and Alexander, 1990; Rudolf et al., 2005; Myers et al., 2010) and apoptosis (Pritchard et al., 2000, 2001; Quinteros et al., 2008). Cr(III) produces damage to cellular proteins, DNA and organelles (Stearns et al., 2002; Raja and Nair, 2008) and can be lethal to organisms and their offspring (Bailey et al., 2006).

He et al. (2007) demonstrated in Hepa 1c1c7 and mouse embryonic fibroblasts cells that Nrf2 protects cells against both apoptosis and ROS production induced by Cr(VI) by the activation of Keap1/Nrf2/ARE. They showed that Nrf2 and Keap1 were ubiquitinated in the cytoplasm and translocated into the nucleus in association with each other. But, both proteins were deubiquitinated upon nuclear translocation. Finally, treatment with Cr(VI) disrupted the Nrf2/Keap1 association in the nucleus, Nrf2 was recruited to the ARE inducing the cytoprotective genes HO-1 and NQO1 expression. Keap1 is shuttled back to the cytoplasm assisting a new round of Nrf2 ubiquitination and activation. It is noteworthy to mention that O'Hara et al. (2006) suggested that Cr(VI) silences induction of ARE-driven genes required for protection from secondary insults in human bronchial epithelial cells. On other side, Kalayarasan et al. (2008) found that potassium dichromate induces a slight activation of Nrf2 in the hepatocytes of Wistar rats.

5.2. Curcumin hepatoprotection

Curcumin has demonstrated protective effects against Cr(VI)-induced toxicity in male reproductive system (Chandra et al., 2007; Devi et al., 2012), kidney (Molina-Jijón et al., 2011) and liver of rodents. Recently, we studied the hepatoprotective effects of curcumin against chromium-induced damage (García-Niño et al., 2013). In rats, we administered curcumin (400 mg/kg) and potassium dichromate (15 mg/kg) and we found that curcumin successfully prevented the Cr(VI)-induced liver injury by reducing hepatocyte damage and the histological alterations, ameliorating lipid and protein oxidation, maintaining the activity of SOD, CAT, GPx, GR and GST, protecting against mitochondrial dysfunction and avoiding the membrane permeability transition pore opening. Apparently, these protective effects of curcumin against chro-

mium-induced liver injury are a consequence of its scavenging activity. Previously, Molina-Jijón et al. (2011) demonstrated that curcumin did not chelate chromium using an *in vitro* system.

6. Copper hepatotoxicity

The liver accounts for approximately 8% of the total amount of copper in the body and represents the tissue with the highest copper concentration (Luza and Speisky, 1996). In this context too low concentrations of copper in tissues induce anemia and too high concentrations induce hepatic damage, however, copper levels in tissues are normally well regulated in healthy animals (Hogstad, 1996). Copper contained in food is absorbed into the portal vein and then loaded into hepatocytes. There, the Cu^{2+} transporting beta polypeptide ATPase (ATP7B) mediates the secretion on one side into the bile and on the other into the bloodstream after linkage to ceruloplasmin, a protein responsible for organized delivery into all tissues (Dijkstra et al., 1996; Tao and Gitlin, 2003; Zhang et al., 2011; Fieten et al., 2012). Chronic copper accumulation in the liver causes hepatitis leading to hepatic failure, pericentral hepatic necrosis, cholestasis, cirrhosis and ultimately death (Chuttani et al., 1965; Hébert et al., 1993; Giuliodori et al., 1997). The hepatocyte cytotoxic mechanisms for copper involve ROS formation, GSH oxidation, lipid peroxidation (Stacey and Klaassen, 1981; Sokol et al., 1994) and mitochondrial dysfunction (Nakatani et al., 1994; Pourahmad and O'Brien, 2000).

6.1. Mechanism of action and Nrf2 induction

The common oxidation states for copper are Cu(I) and Cu(II) and the easy exchange between these two oxidation states endows copper with redox properties that may be of an essential or deleterious nature in biological systems (Peña et al., 1999). The major functions of copper-biological molecules involve oxidation–reduction reactions in which they react directly with molecular oxygen to produce HO \cdot from H_2O_2 and O_2^- via the Fenton and Haber–Weiss reactions which may cause oxidative damage (Gaetke, 2003; Tisato et al., 2010). Copper-induced ROS are important contributing factors in cellular damage that includes lipid peroxidation in membranes, direct oxidation of proteins, and cleavage of DNA and RNA molecules (Peña et al., 1999). Besides, excess cellular copper can disrupt normal cell metabolism by displacing other ions at their metal binding sites or through non-specific binding to enzymes, DNA, and other biomolecules (Alt et al., 1990). Also, copper ions participate in the auto-oxidation of sulfhydryl groups and in the depletion of GSH (Hultberg et al., 1998). Mitochondria are particularly sensitive to oxidative damage because of the excess copper and the resulting oxyradicals may overwhelm cellular defensive mechanisms, compromising respiratory function and further impairing cellular health and survival (Collins et al., 2010).

The induction of Nrf2 mediated by copper has been described in human peripheral blood monocyte-derived macrophages and murine macrophages (RAW264.7) (Calay et al., 2010), human mammary ARE-reporter cell line (AREc32) (Wang et al., 2010), and fetal lung human diploid fibroblasts (Wi-38) (Boilan et al., 2013). Muller et al. (2007) identified genes that provide insight into the adaptive transcriptional response to copper overload-induced oxidative stress in HepG2 cells. They detected increased expression of genes involved in the formation of GSH, GCLM and GCLC, and HO-1 via the transcription factor Nrf2. Korashy and El-Kadi (2006), observed that Cu^{2+} inhibited the constitutive and inducible expression of NQO1 and GST Ya in Hepa 1c1c7 cells, however Cu^{2+} treatment did not alter Nrf2 levels. On the other hand, Piret et al. (2012) studied the toxic effects of copper(II) oxide nanoparticles in HepG2

cells. Transcriptomic data, siRNA knockdown and DNA binding activities suggested that nanoparticles induced activation Nrf2.

6.2. Curcumin hepatoprotection

Protective effects of curcumin against copper-induced toxicity have been studied for genotoxicity (Urbina-Cano et al., 2006; Corona-Rivera et al., 2007), neurotoxicity (Baum and Ng, 2004; Zhao et al., 2010) and liver damage. Wan et al. (2007), in a Wilson disease model, an autosomal recessive disorder of copper metabolism with neuropsychiatric and hepatic symptoms, explored the protective effects of curcumin in copper-overloaded rats. Animals were fed with forage containing copper sulfate (1 g/kg) and in drinking water (0.185%), they were also co-administered curcumin (50 or 200 mg/kg). They observed that in relation to copper-overloaded rats, treatment with curcumin ameliorated lipid peroxidation, recovered the GSH and SOD levels, decreased apoptosis, down-regulated the expression and content of proinflammatory cytokines TNF- α and IL-8 and improved the histological changes induced by copper in liver. This protective effect was explained by the antioxidant and anti-apoptotic properties, in a similar way as has been described in the model of iron overload (Thephinlap et al., 2009; Messner et al., 2010; Qian et al., 2012).

Wan and Luo (2007) demonstrated that curcumin prevented the oxidative damage and the apoptosis induction in Buffalo rat liver cells (BRL) treated with 100 μ mol/L of copper sulfate by reducing ROS and inhibiting c-Jun N-terminal protein kinases (JNK) expression. JNK and p38 are kinases strongly activated by extra- or intracellular stress and inflammatory cytokines that promote the inhibition of cell growth or promotion of cell death (Guo et al., 1998), and curcumin can modulate p38- and JNK-MAPK pathways (Yu et al., 2010; Fan et al., 2012; Topcu-Tarladacalisir et al., 2013). Kou et al. (2013) also recognized the protective effect of curcumin against copper-mediated LDL oxidation because of the upregulation of HO-1, GCLM and CD36 expression in undifferentiated THP-1 cells, suggesting the possible involvement of Keap1/Nrf2/ARE pathway. Thus, curcumin protects against copper-induced hepatic damage by scavenging free radicals, and upregulating the Nrf2/Keap1/ARE pathway. It remains to be determined if there is a possible chelating activity of curcumin against copper hepatotoxicity, as has been previously suggested by Baum and Ng (2004) for copper neurotoxicity.

7. Lead hepatotoxicity

The histopathological alterations that have been described after chronic lead exposure are anisokaryosis, nuclear vesiculation, binucleation, cytoplasmic inclusions and swelling, hydropic degeneration, reduction in glycogen content (Jarrar and Taib, 2012), portal inflammatory cell infiltration (El-Neweshy and El-Sayed, 2011), steatosis, apoptosis and mild fibrosis (Shalan et al., 2005), biliary hyperplasia, edema, congestion and apoptotic and necrotic cells (Mehana et al., 2012).

Acute lead exposure in rodents and in vitro models involves a decrease in hepatic CYP450 content (Degawa et al., 1994; Korashy and El-Kadi, 2012), inhibition of heme synthetic pathway (Lake and Gerschenson, 1978; Jaffe et al., 2001), alterations in hepatic cholesterol metabolism (Kojima et al., 2004; Ademuyiwa et al., 2009), ROS generation, lipid peroxidation (Sandhir and Gill, 1995; Pandya et al., 2010), suppression of activity of antioxidant enzymes and decrease in GSH levels (Daggett et al., 1997, 1998; Korashy and El-Kadi, 2006; Liu et al., 2011), mitochondrial dysfunction (Wielgus-Serafińska et al., 1980; Bragadin et al., 1998, 2007; Pal et al., 2013), oxidative DNA damage (Hernández-Franco et al., 2011; Narayana and Al-Bader, 2011) and apoptosis (Pagliara et al., 2003; Mukherjee et al., 2013).

7.1. Mechanism of action and Nrf2 induction

Lead causes oxidative stress by inducing the generation of ROS, like HO \cdot , O $_2^{\cdot-}$, H $_2$ O $_2$, 1 O $_2$, hydroperoxides (HO $_2$) and lipid peroxides (LPO \cdot) (Valverde et al., 2001; Flora et al., 2004), by reducing the antioxidant defense system of cells via depleting GSH, inhibiting sulfhydryl dependent enzymes or activity of antioxidant enzymes (Gurer and Ercal, 2000; Patil et al., 2006; Patrick, 2006) and/or increasing susceptibility of cells to oxidative attack by altering membrane integrity and fatty acid composition. Another mechanism of free radical generation and adduct formation may involve aminolevulinic acid (ALA), the heme precursor whose levels are elevated by lead exposure through feedback inhibition of the enzyme δ -aminolevulinic acid dehydrogenase (ALAD). As lead, ALA has the tendency to bind to sulfhydryl groups and thus results in overproduction of ROS (Rahman and Sultana, 2006; Gillis et al., 2012). Moreover, lead is able to substitute for other bivalent cations like Ca $^{2+}$, Mg $^{2+}$, Fe $^{2+}$, Zn $^{2+}$ and monovalent cations like Na $^+$, affecting various fundamental biological processes like intra- and intercellular signaling, cell adhesion, protein folding and maturation, apoptosis, ionic transportation, enzyme regulation or release of neurotransmitters (Aboul-Soud et al., 2011; Flora et al., 2012).

Korashy and El-Kadi (2006) were the first to identify that Pb $^{2+}$ and Hg $^{2+}$ regulate the expression of *Nqo1* and *Gsta* genes through Nrf2-ARE-dependent transcriptional mechanisms, inducing the expression of NQO1 and GST Ya mRNAs in a time-dependent manner in Hepa 1c1c7 cells. Recently, Wang et al. (2013a,b) showed evidence supporting the up-regulation of Nrf2 and MRP1 in response to lead-induced oxidative and electrophilic stress in rat testes. MRP1 is a plasma membrane glycoprotein that can confer multidrug resistance by increased export of drugs from the cell resulting in a decreased intracellular drug concentration (Zaman et al., 1995).

7.2. Curcumin hepatoprotection

Curcumin has shown protective effects in rodents against lead neurotoxicity (Shukla et al., 2003; Daniel et al., 2004; Dairam et al., 2007), cardiotoxicity (Asali et al., 2011; Roshan et al., 2011a, 2012), nephrotoxicity (Farzanegi et al., 2012; Ghoniem et al., 2012; Sangartit et al., 2012), immunotoxicity (El-Sherbiny et al., 2010), bone disease (Roshan et al., 2011b) and hepatotoxicity. El-Ashmawy et al. (2006) studied the hepatoprotective potential of turmeric powder against lead-induced liver toxicity by feeding mice with a diet supplemented with lead acetate (0.5%) and turmeric (1% or 5%). Turmeric co-treatment prevented the decrease in the GST activity and ameliorated lipid peroxidation, but the level of GSH was slightly decreased in liver. Due to its content of polyphenolic compounds, like curcumin, two possible mechanisms were proposed by which turmeric could protect liver, by scavenging ROS and chelating this toxic metal. Also, turmeric protects against lead-induced genotoxicity in bone marrow chromosomes.

On the other hand, Memarmoghaddam et al. (2011) determined the effect of exercise training and curcumin supplementation on lead-induced oxidative damage in liver. Mice performed progressive running training sessions and they received curcumin solution (30 mg/kg) and lead acetate (20 mg/kg). In this way, curcumin, endurance training and the combination reduce the heat shock protein levels and lipid peroxidation generated by lead exposure. These authors suggested that aerobic exercise and anti-oxidant supplements might have beneficial effects for health. Recently, Flora et al. (2013) evaluated the protective efficacy of curcumin and nanocurcumin against lead-induced toxicity in blood, liver, kidney and brain. Mice were co-administered lead acetate (25 mg/kg) and curcumin (15 mg/kg) or nanocurcumin (15 mg/

kg). In liver, curcumin and nanocurcumin showed beneficial effects by protecting against lipid peroxidation, protein oxidation and restoring altered ROS levels, GSH and glutathione disulfide (GSSG). Interestingly, the hepatoprotection by curcumin and nanocurcumin was similar. In contrast, lead concentration was determined in liver tissue and it was found that curcumin and nanocurcumin both reduced lead content, but that nanocurcumin showed a greater chelating effect than curcumin. It is worth mentioning that in blood, curcumin and nanocurcumin re-established ALAD activity and the protective effects in kidney and brain were similar, nanocurcumin being more effective than curcumin. Thus, the scavenging and chelating properties of curcumin seems to be mainly

responsible for the protective effect against lead-induced hepatotoxicity. It has also been demonstrated that increasing curcumin's bioavailability will make a more effective hepatoprotective agent. However, it remains unclear whether curcumin can activate Nrf2/Keap1/ARE pathway in models of hepatotoxicity caused by lead poisoning.

8. Mercury hepatotoxicity

Hepatocellular effects described for mercury are elevated serum ALT, ornithine carbamyltransferase and serum bilirubin levels,




Fig. 5. Protective effect of curcumin against heavy-metals induced-hepatic damage. Arsenic (As), cadmium (Cd), chromium (Cr), copper (Cu), mercury (Hg), lead (Pb), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST), glutathione (GSH), reactive oxygen species (ROS), nuclear factor (erythroid-derived 2)-like 2 (Nrf2), antioxidant responsive element (ARE), Kelch-like ECH-associated protein 1 (Keap1), hepatic stellate cells (HSC), mitochondrial membrane potential ($\Delta\Psi_m$), metallothionein (MT), tumor necrosis factor- α (TNF- α) and interleukin-8 (IL-8).

850 hepatomegaly and centrilobular hepatic steatosis, decrease in the
851 synthesis of hepatic coagulation factors (Kanluen and Gottlieb,
852 1991; Ashour et al., 1993; Joshi et al., 2011, 2012; Cao et al.,
853 2012), decreased activity of metabolic enzymes (Chang et al.,
854 1973), increase in lipid peroxidation products (Stacey and
855 Kappus, 1982; Benov et al., 1990; Huang et al., 1996; Lin et al.,
856 1996), mitochondrial dysfunction (Belyaeva et al., 2011), prolifera-
857 tion of the endoplasmic reticulum, floccular degeneration of the
858 hepatic mitochondria with extrusion of degenerated hepatic
859 organelles and cytoplasmic debris into the sinusoidal space and
860 engulfed by Kupffer cells and vacuolar degeneration of the mito-
861 chondria in the Kupffer cells (Chang and Yamaguchi, 1974;
862 Desnoyers and Chang, 1975a,b).

863 **8.1. Mechanism of action and Nrf2 induction**

864 Exposure to mercury compounds induces oxidative stress
865 (Atchison and Hare, 1994; Mahboob et al., 2001; Gutierrez et al.,
866 2006; Al-azzawie et al., 2013; Farina et al., 2013). Mercury induces
867 the formation of H₂O₂, ROO[•] and HO[•] that may cause cell membrane
868 damage and cell death (Miller et al., 1991; Hussain et al., 1999),
869 inhibition of the activity of antioxidant enzymes such as CAT, SOD
870 and GPx (Benov et al., 1990; Sener et al., 2007; Franco et al.,
871 2009; Pal and Ghosh, 2012), depletion of GSH, decrease of the sulf-
872 hydryl groups of proteins (Hultberg et al., 1998, 2001; Farina et al.,
873 2011; Bridges et al., 2012), interference with enzyme functions and
874 disturbance in both protein synthesis and energy production (Zahir
875 et al., 2006; Castro-González and Méndez-Armenta, 2008;
876 Ragunathan et al., 2010; Amara and El-Kadi, 2011). The mitochon-
877 drion is a primary target of mercury-induced injury and the mito-
878 chondrial electron transport chain is the most likely site where
879 excess ROS are generated to induce oxidative stress in mercury tox-
880 icity (Yee and Choi, 1996). Mitochondrial effects of mercury *in vivo*
881 and *in vitro*, include mitochondrial dysfunction (Chávez and
882 Holguín, 1988; Chávez et al., 1989; Hare and Atchison, 1992;
883 Dreiem et al., 2005; Hernández-Esquivel et al., 2011), membrane
884 permeability transition pore opening (Limke and Atchison, 2002;
885 Polunas et al., 2011) and apoptosis (Shenker et al., 1999; Kim and
886 Sharma, 2004; Humphrey et al., 2005).

887 In contrast with Cu²⁺ treatment, it has been described that mer-
888 cury increases Nrf2 levels in human monocytes (Wataha et al.,
889 2008). Korashy and El-Kadi (2006) identified that Hg²⁺ and Pb²⁺
890 regulate the expression of *Nqo1* and *Gstya* genes through Nrf2/
891 Keap1/ARE pathway in Hepa 1c1c7 cells. Later, Amara and
892 El-Kadi (2011) examined the effect of Hg²⁺ on the expression of
893 NQO1 in HepG2 cells. In this case, Hg²⁺ treatment increased
894 activity, protein, and mRNA of NQO1, which was associated with
895 increased nuclear accumulation of Nrf2 protein and ARE activation.

896 **8.2. Curcumin hepatoprotection**

897 Despite the fact that curcumin has the potential to prevent or
898 protect against noxious effects induced by heavy metals, its poten-
899 tially protective role against mercury toxicity has been poorly
900 studied. Agarwal et al. (2010) demonstrated that curcumin
901 (80 mg/kg) pretreatment and post-treatment had a protective
902 effect on mercury-induced oxidative stress in the liver, kidneys
903 and brain of rats treated with mercuric chloride (12 μmol/kg).
904 Moreover, curcumin reestablished the antioxidant enzyme activi-
905 ties, reversed mercury-induced liver and kidney injury markers
906 and modified the expression of metallothionein mRNA. Also, cur-
907 cumin chelates mercury in this model by reducing its concentra-
908 tion in these tissues. However, mercury-induced histological
909 alterations were not prevented by curcumin treatment. Appar-
910 ently, curcumin protects against mercury-induced hepatic damage

911 by scavenging free radicals and chelating this metal. Furthermore,
912 it is important to evaluate the participation of Nrf2/Keap1/ARE
913 pathway as a protective mechanism induced by curcumin.

914 **9. Summary and conclusions**

915 Heavy metals are persistent and widespread pollutants that
916 affect the structure and function of several organs by generating
917 oxidative stress. Liver is a sensitive organ affected by arsenic,
918 cadmium, chromium, copper, lead and mercury exposure. How-
919 ever, the antioxidant, anti-inflammatory, anti-fibrogenic and anti-
920 carcinogenic activities of curcumin may confer therapeutic efficacy
921 against different environmental or occupational hepatic toxins. In
922 this manner, curcumin can protect against the toxic effects of
923 heavy metals on the liver by reducing the structural damage, pre-
924 venting lipid peroxidation, avoiding GSH depletion, maintaining
925 the activity of SOD, CAT, GPx, GR, GST and NQO1 and protecting
926 against the following liver mitochondrial alterations: oxidative
927 phosphorylation-disruption, decrease in the cellular ATP levels,
928 mitochondrial permeability transition, calcium homeostasis dis-
929 ruption and apoptosis (Fig. 5). These protective effects of curcumin
930 were attributed to its ability to scavenge free radicals, to act as a
931 chelating agent and/or its capacity to induce detoxifying enzymes
932 by upregulation of the Keap1/Nrf2/ARE pathway (Fig. 4). In addi-
933 tion, curcumin down-regulated NF-κB as well as the expression
934 and content of proinflammatory cytokines preventing noxious
935 effects induced by heavy metals in the liver. In addition, the devel-
936 opment of new strategies or technologies that improves curcu-
937 min's bioavailability could result in greater protection against
938 liver damage caused by these agents. Another field that has not
939 been studied in depth is related to the role of curcumin as a protec-
940 tive agent against mitochondrial dysfunction induced directly or
941 indirectly by the oxidative stress generated by heavy metals.
942 Despite the great potential of curcumin to prevent heavy metals-
943 induced hepatotoxicity, the number of studies is still limited. As
944 a result, additional research about physiological, cellular and
945 molecular mechanisms involved in curcumin hepatoprotection
946 are needed, in order to propose it as a potential therapeutic agent
947 against oxidative damage generated by exposure to heavy metals.

948 **Conflict of Interest**

949 The authors declare that there are no conflicts of interest.

950 **Transparency Document**

951 The [Transparency document](#) associated with this article can be
952 found in the online version.

953 **10. Uncited reference**

954 Tarasub et al. (2008).

955 **Acknowledgements**

956 The authors thank funding from the National Council of Science
957 and Technology (CONACYT 129838) and the Project Support Pro-
958 gramme for Research and Technological Innovation (PAPIIT
959 IN210713) that support in part the preparation of this manuscript.
960

961 **References**

962 Abiko, Y., Shinkai, Y., Sumi, D., Kumagai, Y., 2010. Reduction of arsenic-induced
963 cytotoxicity through Nrf2/HO-1 signaling in HepG2 cells. *J. Toxicol. Sci.* 35, 419–
964 423.

- Aboul-Soud, M. A. M., Al-Othman, A.M., El-Desoky, G.E., Al-Othman, Z. a., Yusuf, K., Ahmad, J., Al-Khedhairi, A. a., 2011. Hepatoprotective effects of vitamin E/ selenium against malathion-induced injuries on the antioxidant status and apoptosis-related gene expression in rats. *J. Toxicol. Sci.* 36, 285–296.
- Acharya, S., Mehta, K., Krishnan, S., Rao, C., 2001. A subtoxic interactive toxicity of ethanol and chromium in male Wistar rats. *Alcohol* 23, 99–108.
- Ademuyiwa, O., Agarwal, R., Chandra, R., Behari, J.R., 2009. Lead-induced phospholipidosis and cholesterologenesis in rat tissues. *Chem. Interact.* 179, 314–320.
- Agarwal, R., Goel, S., Behari, J., 2010. Detoxification and antioxidant effects of curcumin in rats experimentally exposed to mercury. *J. Appl. Toxicol.* 30, 457–468.
- Aggarwal, B., Kumar, A., Bharti, A., 2003. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res.* 23, 363–398.
- Aggarwal, B.B., Ichikawa, H., Garodia, P., Weerasinghe, P., Sethi, G., Bhatt, I.D., Pandey, M.K., Shishodia, S., Nair, M.G., 2006. From traditional ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. *Expert Opin. Ther. Targets* 10, 87–118.
- Aggarwal, B., Bhatt, I., Ichikawa, H., Ahn, K., Sethi, G., Sandur, S., Natarajan, C., Seeram, N., Shishodia, S., 2007. Curcumin – biological and medicinal properties. *Turmeric genus Curcuma; Med Aromat plants-industrial profiles* CRC Press United States Am, 297–368.
- Ahalya, N., Ramachandra, T.V., Kanamadi, R.D., 2003. Biosorption of heavy metals. *Res. J. Chem. Environ.* 7, 71–79.
- Ahsan, H., Parveen, N., Khan, N.U., Hadi, S.M., 1999. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. *Chem. Biol. Interact.* 121, 161–175.
- Ak, T., Gülcin, I., 2008. Antioxidant and radical scavenging properties of curcumin. *Chem. Biol. Interact.* 174, 27–37.
- Al-azzawie, H.F., Umran, A., Hyader, N.H., 2013. Oxidative stress, antioxidant status and DNA damage in a mercury exposure workers. *Br. J. Pharmacol. Toxicol.* 4, 80–88.
- Alexander, J., Aaseth, J., 1995. Uptake of chromate in human red blood cells and isolated rat liver cells: the role of the anion carrier. *Analyst* 120, 931–933.
- Alghasham, A., Ta, S., Ar, M., 2013. Effect of cadmium-polluted water on plasma levels of tumor necrosis factor- α , interleukin-6 and oxidative status biomarkers in rats: protective effect of curcumin. *Food Chem. Toxicol.* 59, 160–164.
- Al-Hujaili, E.M., Mohamed, A.G., Al-Sharif, I., Youssef, K.M., Manogaran, P.S., Al-Otaibi, B., Al-Haza'a, A., Al-Jammaz, I., Al-Hussein, K., Aboussekhra, A., 2011. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. *Breast Cancer Res. Treat.* 128, 97–107.
- Alissa, E., Ferns, G., 2011. Heavy metal poisoning and cardiovascular disease. *J. Toxicol.* 2011, 1–21.
- Al-Jassabi, S., Ahmed, K.A., Ameen, M., 2012. Antioxidant effect of curcumin against microcystin-LR-induced renal oxidative damage in Balb/c mice. *Trop. J. Pharm. Res.* 11, 531–536.
- Allegri, P., Mastromarino, A., Neri, P., 2010. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. *Clin. Ophthalmol.* 4, 1201–1206.
- Al-Nasser, I., 2000. Cadmium hepatotoxicity and alterations of the mitochondrial function. *J. Toxicol. Clin. Toxicol.* 38, 407–413.
- Alt, E., Sternlieb, I., Goldfischer, S., 1990. The cytopathology of metal overload. *Int. Rev. Exp. Pathol.* 31, 165–188.
- Altenburg, J.D., Bieberich, A.A., Terry, C., Harvey, K.A., Vanhorn, J.F., Xu, Z., Davisson, V.J., Siddiqui, R.A., 2011. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. *BMC Cancer* 11, 149.
- Amara, I.E.A., El-Kadi, A.O.S., 2011. Transcriptional modulation of the NAD(P)H:quinone oxidoreductase 1 by mercury in human hepatoma HepG2 cells. *Free Radic. Biol. Med.* 51, 1675–1685.
- Ammon, H.P., Wahl, M.A., 1991. *Pharmacology of Curcuma longa*. *Planta Med.* 57, 1–7.
- Anand, S.S., 2005. Protective effect of vitamin B6 in chromium-induced oxidative stress in liver. *J. Appl. Toxicol.* 25, 440–443.
- Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., 2007. Bioavailability of curcumin: problems and promises. *Mol. Pharm.* 4, 807–818.
- Anand, P., Thomas, S.G., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Sung, B., Tharakan, S.T., Misra, K., Priyadarsini, I.K., Rajasekharan, K.N., Aggarwal, B.B., 2008. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. *Biochem. Pharmacol.* 76, 1590–1611.
- Anwar-Mohamed, A., Elshenawy, O.H., Soshilov, A.A., Denison, M.S., Le, X.C., Klotz, L., El-Kadi, A.O.S., 2013. Methylated pentavalentarsenic metabolites are bifunctional inducers as they induce cytochrome P450 1A1 (CYP1A1) and NAD(P)H:quinone oxidoreductase (NQO1) through AhR and Nrf2 dependent mechanisms. *Free Radic. Biol. Med.*
- Aono, J., Yanagawa, T., Itoh, K., Li, B., Yoshida, H., Kumagai, Y., Yamamoto, M., Ishii, T., 2003. Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. *Biochem. Biophys. Res. Commun.* 305, 271–277.
- Asali, M., Roshan, V.D., Hosseinzadeh, S., Mahjoub, S., Moghaddam, A.H., 2011. The role of exercising and curcumin on the treatment of lead-induced cardiotoxicity in rats. *Iran. J. Health Phys. Act.* 2, 1–5.
- Ashour, H., Abdel-Rahman, M., Khodair, A., 1993. The mechanism of methyl mercury toxicity in isolated rat hepatocytes. *Toxicol. Lett.* 69, 87–96.
- Atchison, W., Hare, M., 1994. Mechanisms of methylmercury-induced neurotoxicity. *FASEB J.* 8, 622–629.
- Bagchi, D., Hassoun, E., Bagchi, M., Muldoon, D., Stohs, S., 1995a. Oxidative stress induced by chronic administration of sodium dichromate [Cr(VI)] to rats. *Comp. Biochem. Physiol.* 110, 281–287.
- Bagchi, D., Hassoun, E., Bagchi, M., Stohs, S., 1995b. Chromium-induced excretion of urinary lipid metabolites, DNA damage, nitric oxide production, and generation of reactive oxygen species in Sprague-Dawley rats. *Comp. Biochem. Physiol.* 110, 177–187.
- Bagchi, D., Bagchi, M., Stohs, S., 2001. Chromium (VI)-induced oxidative stress, apoptotic cell death and modulation of p53 tumor suppressor gene. *Mol. Cell. Biochem.* 222, 149–158.
- Bailey, M., Boohaker, J., Sawyer, R., Behling, J., Rasco, J., Jernigan, J., Hood, R., Vincent, J., 2006. Exposure of pregnant mice to chromium picolinate results in skeletal defects in their offspring. *Birth Defects Res. B Dev. Reprod. Toxicol.* 77, 244–249.
- Balasubramanyam, M., Koteswari, A.A., Kumar, R.S., Monickaraj, S.F., Maheswari, J.U., Mohan, V., 2003. Curcumin-induced inhibition of cellular reactive oxygen species generation: novel therapeutic implications. *J. Biosci.* 28, 715–721.
- Balogun, E., Hoque, M., Gong, P., Killeen, E., Green, C.J., Foresti, R., Alam, J., Motterlini, R., 2003. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. *Biochem. J.* 371, 887–895.
- Banji, D., Banji, O.J.F., Dasaraju, S., Kumar, C.H.K., 2013. Curcumin and piperine abrogate lipid and protein oxidation induced by D-galactose in rat brain. *Brain Res.* 1515, 1–11.
- Barthelemy, S., Vergnes, L., Moynier, M., Guyot, D., Labidalle, S., Bahraoui, E., 1998. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. *Res. Virol.* 149, 43–52.
- Bashir, S., Sharma, Y., Irshad, M., Nag, T.C., Tiwari, M., Kabra, M., Dogra, T., 2006. Arsenic induced apoptosis in rat liver following repeated 60 days exposure. *Toxicology* 217, 63–70.
- Basnet, P., Skalko-Basnet, N., 2011. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. *Molecules* 16, 4567–4598.
- Baum, L., Ng, A., 2004. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. *J. Alzheimer's Dis.* 6, 367–377.
- Belcaro, G., Cesarone, M.R., Dugall, M., Pellegrini, L., Ledda, A., Grossi, M.G., Togni, S., Appendino, G., 2010. Efficacy and safety of Meriva[®], a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. *Altern. Med. Rev.* 15, 337–344.
- Belyaeva, E., Korotkov, S.M., Saris, N.-E., 2011. In vitro modulation of heavy metal-induced rat liver mitochondria dysfunction: a comparison of copper and mercury with cadmium. *J. Trace Elem. Med. Biol.* 25S, S63–S73.
- Benov, L.C., Benchev, I.C., Monovich, O.H., 1990. Thiol antidotes effect on lipid peroxidation in mercury-poisoned rats. *Chem. Biol. Interact.* 76, 321–332.
- Bereswill, S., Muñoz, M., Fischer, A., Plickert, R., Haag, L., Otto, B., Kühl, A., Lodenkemper, C., Göbel, U., Heimesaat, M., 2010. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. *PLoS One*, e15099.
- Bernhoft, R.A., 2013. Cadmium toxicity and treatment. *Sci. World J.* 2013, 1–7.
- Bhullar, K.S., Jha, A., Youssef, D., Rupasinghe, H.P.V., 2013. Curcumin and its carbocyclic analogs: structure-activity in relation to antioxidant and selected biological properties. *Molecules* 18, 5389–5404.
- Biswas, J., Roy, S., Mukherjee, S., Sinha, D., Roy, M., 2010a. Indian spice curcumin may be an effective strategy to combat the genotoxicity of arsenic in Swiss albino mice. *Asian Pacific J. Cancer Prev.* 11, 239–247.
- Biswas, J., Sinha, D., Mukherjee, S., Roy, S., Siddiqui, M., Roy, M., 2010b. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. *Hum. Exp. Toxicol.* 29, 513–524.
- Boilan, E., Winant, V., Dumortier, E., Piret, J.-P., Bonfitto, F., Osiewacz, H.D., Debacq-Chainiaux, F., Toussaint, O., 2013. Role of p38MAPK and oxidative stress in copper-induced senescence. *Age (Omaha)* 35, 2255–2271.
- Bragadin, M., Marton, D., Murgia, M., Rizzoli, V., Scutari, G., Deana, R., 1998. Interactions of trialkyllead compounds with rat liver mitochondria. *J. Inorg. Biochem.* 69, 259–262.
- Bragadin, M., Marton, D., Manente, S., 2007. Trialkyllead compounds induce the opening of the MTP pore in rat liver mitochondria. *J. Inorg. Biochem.* 101, 876–878.
- Bridges, C.C., Krasnikov, B.F., Joshee, L., Pinto, J.T., Hallen, A., Li, J., Zalups, R.K., Cooper, A.J.L., 2012. New insights into the metabolism of organomercury compounds: mercury-containing cysteine S-conjugates are substrates of human glutamine transaminase K and potent inactivators of cystathionine γ -lyase. *Arch. Biochem. Biophys.* 517, 20–29.
- Bucio, L., Souza, V., Albores, A., Sierra, A., Chávez, E., Cárbaz, A., Gutiérrez-Ruiz, M., 1995. Cadmium and mercury toxicity in a human fetal hepatic cell line (WRL-68 cells). *Toxicology* 102, 285–299.
- Buelna-Chontal, M., Zazueta, C., 2013. Redox activation of Nrf2 & NF- κ B: a double end sword? *Cell Signal.* 25, 2548–2557.
- Calay, D., Rousseau, A., Mattart, L., Nuyens, V., Delporte, C., Van Antwerpen, P., Arnould, T., Boudjeltia, K.Z., Raes, M., 2010. Copper and myeloperoxidase-modified LDLs activate Nrf2 through different pathways of ROS production in macrophages. *Antioxidants Redox Signal.* 13, 1491–1502.
- Cannino, G., Ferruggia, E., Luparello, C., Rinaldi, A., 2009. Cadmium and mitochondria. *Mitochondrion* 9, 377–384.

1135 Cao, Y., Chen, X., Zhou, Z., Zhang, Z., Jiang, X., Jin, R., Chen, H., 2012. Study on
1136 different doses of mercury-containing preparations on acute toxicity in rabbits].
1137 China J. Chin. Mater. Med. 37, 723–727.

1138 Casalino, E., Calzaretto, G., Sblano, C., Landriscina, C., 2002. Molecular inhibitory
1139 mechanisms of antioxidant enzymes in rat liver and kidney by cadmium.
1140 Toxicology 179, 37–50.

1141 Casalino, E., Sblano, C., Calzaretto, G., Landriscina, C., 2006. Acute cadmium
1142 intoxication induces alpha-class glutathione S-transferase protein synthesis
1143 and enzyme activity in rat liver. Toxicology 217, 240–245.

1144 Casalino, E., Calzaretto, G., Landriscina, M., Sblano, C., Fabiano, A., Landriscina, C.,
1145 2007. The Nrf2 transcription factor contributes to the induction of alpha-class
1146 GST isoenzymes in liver of acute cadmium or manganese intoxicated rats:
1147 comparison with the toxic effect on NAD(P)H:quinone reductase. Toxicology
1148 237, 24–34.

1149 Castro-González, M.I., Méndez-Armenta, M., 2008. Heavy metals: implications
1150 associated to fish consumption. Environ. Toxicol. Pharmacol. 26, 263–271.

1151 CDC, 2009. Fourth National report on human exposure to environmental chemicals.
1152 Department of Health and Human Services. Centers for Disease Control and
1153 Prevention.

1154 Chainani-Wu, N., 2003. Safety and anti-inflammatory activity of curcumin: a
1155 component of turmeric (*Curcuma longa*). J. Altern. Complement. Med. 9, 161–
1156 168.

1157 Chandra, A., Chatterjee, A., Ghosh, R., Sarkar, M., 2007. Effect of curcumin on
1158 chromium-induced oxidative damage in male reproductive system. Environ.
1159 Toxicol. Pharmacol. 24, 160–166.

1160 Chandran, B., Goel, A., 2012. A randomized, pilot study to assess the efficacy and
1161 safety of curcumin in patients with active rheumatoid arthritis. Phytother. Res.
1162 26, 1719–1725.

1163 Chang, L., Yamaguchi, S., 1974. Ultrastructural changes in the liver after long-term
1164 diet of mercury-contaminated tuna. Environ. Res. 7, 133–148.

1165 Chang, L.W., Ware, R.A., Desnoyers, P.A., 1973. A histochemical study on some
1166 enzyme changes in the kidney, liver and brain after chronic mercury
1167 intoxication in the rat. Food Cosmet. Toxicol. 11, 283–286.

1168 Chang, Y., Wen, J., Cai, J., Xiao-Ying, W., Yang, L., Yd, G., 2012. An investigation and
1169 pathological analysis of two fatal cases of cadmium poisoning. Forensic Sci. Int.
1170 220, 1–3.

1171 Chattopadhyay, I., Biswas, K., Bandyopadhyay, U., Banerjee, R.K., 2004. Turmeric and
1172 curcumin: biological actions and medicinal applications. Curr. Sci. 87, 44–53.

1173 Chávez, E., Holguín, J.A., 1988. Mitochondrial calcium release as induced by Hg²⁺. J.
1174 Biol. Chem. 263, 3582–3587.

1175 Chávez, E., Briones, R., Michel, B., Bravo, C., Jay, D., 1985. Evidence for the
1176 involvement of dithiol groups in mitochondrial calcium transport: studies with
1177 cadmium. Arch. Biochem. Biophys. 242, 493–497.

1178 Chávez, E., Zazueta, C., Diaz, E., Holguín, J., 1989. Characterization by Hg²⁺ of two
1179 different pathways for Ca²⁺ release. Biochim. Biophys. Acta 986, 27–32.

1180 Chen, J., Shaikh, Z.A., 2009. Activation of Nrf2 by cadmium and its role in protection
1181 against cadmium-induced apoptosis in rat kidney cells. Toxicol. Appl.
1182 Pharmacol. 241, 81–89.

1183 Chen, B., Burt, C., Goering, P., Fowler, B., London, R., 1986. In vivo 31P nuclear
1184 magnetic resonance studies of arsenite induced changes in hepatic phosphate
1185 levels. Biochem. Biophys. Res. Commun. 139, 228–234.

1186 Chen, S., Chen, Y., Li, Y., Chen, S., Tan, J., Ou, T., Gu, L., Huang, Z., 2011. Design,
1187 synthesis, and biological evaluation of curcumin analogues as multifunctional
1188 agents for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 19, 5596–
1189 5604.

1190 Cheng, A.L. et al., 2001. Phase I clinical trial of curcumin, a chemopreventive agent,
1191 in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 2895–
1192 2900.

1193 Chuttani, H., Gupta, P., Gulati, S., Gupta, D., 1965. Acute copper sulfate poisoning.
1194 Am. J. Med. 39, 849–854.

1195 Çikriñçi, S., Mozioglu, E., Yilmaz, H., 2008. Biological activity of curcuminoids
1196 isolated from *Curcuma longa*. Rec. Nat. Prod. 2, 19–24.

1197 Collins, S., McCoy, K., Catapane, E., Carroll, M., 2010. The effects of copper and copper
1198 blocking agents on gill mitochondrial O₂ utilization of *Crassostrea virginica*. In
1199 Vivo (Brooklyn) 32, 14–19.

1200 Copple, I.M., Goldring, C.E., Kitteringham, N., Park, B.K., 2008. The Nrf2-Keap1
1201 defence pathway: role in protection against drug-induced toxicity. Toxicology
1202 246, 24–33.

1203 Cordova, E., Valenzuela, O., Sánchez-Peña, L., Escamilla-Guerrero, G., Hernández-
1204 Zavala, A., Orozco, L., Razo, L., 2013. Nuclear factor erythroid 2-related factor
1205 gene variants and susceptibility of arsenic-related skin lesions. Hum. Exp.
1206 Toxicol.

1207 Corona-Rivera, A., Urbina-Cano, P., Bobadilla-Morales, L., Vargas-Lares, J., Ramirez-
1208 Herrera, M., Mendoza-Magaya, M., Troyo-Sanroman, R., Diaz-Esquivel, P.,
1209 Corona-Rivera, J., 2007. Protective in vivo effect of curcumin on copper
1210 genotoxicity evaluated by comet and micronucleus assays. J. Appl. Genet. 48,
1211 389–396.

1212 Correa, F., Buelna-Chontal, M., Hernández-Reséndiz, S., García-Niño, W.R., Roldán,
1213 F.J., Soto, V., Silva-Palacios, A., Amador, A., Pedraza-Chaverrí, J., Tapia, E.,
1214 Zazueta, C., 2013. Curcumin maintains cardiac and mitochondrial function in
1215 chronic kidney disease. Free Radic. Biol. Med. 61, 119–129.

1216 Cruz-Correa, M., Shoskes, D.A., Sanchez, P., Zhao, R., Hyland, L.M., Wexner, S.D.,
1217 Giardiello, F.M., 2006. Combination treatment with curcumin and quercetin of
1218 adenomas in familial adenomatous polyposis. Clin. Gastroenterol. Hepatol. 4,
1219 1035–1038.

Cullinan, S.B., Gordan, J.D., Jin, J., Harper, J.W., Diehl, J.A., 2004. The Keap1-BTB
1220 protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative
1221 stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 24, 8477–8486.

1222 Daggett, D.A., Nuwaysir, E.F., Nelson, S.A., Wright, L.S., Kornguth, S.E., Siegel, F.L.,
1223 1997. Effects of triethyl lead administration on the expression of glutathione S-
1224 transferase isoenzymes and quinone reductase in rat kidney and liver.
1225 Toxicology 117, 61–71.

1226 Daggett, D.A., Oberley, T.D., Nelson, S.A., Wright, L.S., Kornguth, S.E., Siegel, F.L.,
1227 1998. Effects of lead on rat kidney and liver: GST expression and oxidative
1228 stress. Toxicology 128, 191–206.

1229 Dairam, A., Limson, J.L., Watkins, G.M., Antunes, E., Daya, S., 2007. Curcuminoids,
1230 curcumin, and demethoxycurcumin reduce lead-induced memory deficits in
1231 male Wistar rats. J. Agric. Food Chem. 55, 1039–1044.

1232 Dairam, A., Fogel, R., Daya, S., Limson, J.L., 2008. Antioxidant and iron-binding
1233 properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in
1234 rat brain homogenate. J. Agric. Food Chem. 56, 3350–3356.

1235 Daniel, S., Limson, J.L., Dairam, A., Watkins, G.M., Daya, S., 2004. Through metal
1236 binding, curcumin protects against lead- and cadmium-induced lipid
1237 peroxidation in rat brain homogenates and against lead-induced tissue
1238 damage in rat brain. J. Inorg. Biochem. 98, 266–275.

1239 Das, L., Vinayak, M., 2012. Anti-carcinogenic action of curcumin by activation of
1240 antioxidant defence system and inhibition of NF-κB signalling in lymphoma-
1241 bearing mice. Biosci. Rep. 32, 161–170.

1242 Das, S., Santra, A., Lahiri, S., Guha Mazumder, D., 2005. Implications of oxidative
1243 stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis
1244 of hepatic collagenesis in chronic arsenic toxicity. Toxicol. Appl. Pharmacol. 204,
1245 18–26.

1246 Das, N., Paul, S., Chatterjee, D., Banerjee, N., Majumder, N., Sarma, N., Sau, T., Basu, S.,
1247 Banerjee, S., Majumder, P., Bandyopadhyay, A., States, J., Giri, A., 2012. Arsenic
1248 exposure through drinking water increases the risk of liver and cardiovascular
1249 diseases in the population of West Bengal, India. BMC Public Health 12, 639.

1250 Deevika, B., Asha, S., Taju, G., Nalini, T., 2012. Cadmium acetate induced
1251 nephrotoxicity and protective role of curcumin in rats. Asian J. Pharm. Clin.
1252 Res. 5, 186–188.

1253 Degawa, M., Arai, H., Kubota, M., Hashimoto, Y., 1994. Ionic lead, a unique metal ion
1254 as an inhibitor for cytochrome P450IA2 (CYP1A2) expression in the rat liver.
1255 Biochem. Biophys. Res. Commun. 200, 1086–1092.

1256 Deodhar, S.D., Sethi, R., C. SR., 1980. Preliminary study on antirheumatic activity of
1257 curcumin (diferuloyl methane). Indian J. Med. Res. 71, 632–634.

1258 Desnoyers, P.A., Chang, L.W., 1975a. Ultrastructural changes in rat hepatocytes
1259 following acute methyl mercury intoxication. Environ. Res. 9, 224–239.

1260 Desnoyers, P.A., Chang, L.W., 1975b. Ultrastructural changes in the liver after
1261 chronic exposure to methylmercury. Environ. Res. 10, 59–75.

1262 Devi, K.R., Mosherajiu, M., Reddy, K.D., 2012. Curcumin prevents chromium induced
1263 sperm characteristics in mice. IOSR J. Pharm. 2, 312–316.

1264 Dhillon, N., Aggarwal, B.B., Newman, R.A., Wolff, R.A., Kunnumakkara, A.B.,
1265 Abbruzzese, J.L., Ng, C.S., Badmaev, V., Kurzrock, R., 2008. Phase II trial of
1266 curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14,
1267 4491–4499.

1268 Dhule, S.S., Penforinis, P., Frazier, T., Walker, R., Feldman, J., Tan, G., He, J., Alb, A.,
1269 John, V., Pochampally, R., 2012. Curcumin-loaded γ-cyclodextrin liposomal
1270 nanoparticles as delivery vehicles for osteosarcoma. Nanomed. Nanotechnol.,
1271 Biol. Med. 8, 440–451.

1272 Dijkstra, M., van den Berg, G., Wolters, H., Ift Veld, G., Slooff, M., Heymans, H.,
1273 Kuipers, F., Vonk, R., 1996. Adenosine triphosphate-dependent copper transport
1274 in human liver. J. Hepatol. 25, 37–42.

1275 Ding, M., Shi, X., 2002. Molecular mechanisms of Cr(VI)-induced carcinogenesis.
1276 Mol. Cell. Biochem. 234–235, 293–300.

1277 Dinkova-Kostova, A.T., Talalay, P., 1999. Relation of structure of curcumin analogs to
1278 their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis
1279 20, 911–914.

1280 Dinkova-Kostova, A., Talalay, P., 2008. Direct and indirect antioxidant properties of
1281 inducers of cytoprotective proteins. Mol. Nutr. Food Res. 52, S128–S138.

1282 Dinkova-Kostova, A.T., Massiah, M.A., Bozak, R.E., Hicks, R.J., Talalay, P., 2001.
1283 Potency of Michael reaction acceptors as inducers of enzymes that protect
1284 against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc.
1285 Natl. Acad. Sci. USA 98, 3404–3409.

1286 Dinkova-Kostova, A.T., Holtzclaw, W.D., Cole, R.N., Itoh, K., Wakabayashi, N.,
1287 Katoh, Y., Yamamoto, M., Talalay, P., 2002. Direct evidence that sulfhydryl
1288 groups of Keap1 are the sensors regulating induction of phase 2 enzymes that
1289 protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. USA 99,
1290 11908–11913.

1291 Donatus, I., Sardjoko, Vermeulen, N., 1990. Cytotoxic and cytoprotective activities of
1292 curcumin. Effects on paracetamol-induced cytotoxicity, lipid peroxidation and
1293 glutathione depletion in rat hepatocytes. Biochem. Pharmacol. 39, 1869–1875.

1294 Dong, Z., 2002. The molecular mechanisms of arsenic-induced cell transformation
1295 and apoptosis. Environ. Health Perspect. 110, 757–759.

1296 Dreiem, A., Gertz, C.C., Seegal, R.F., 2005. The effects of methylmercury on
1297 mitochondrial function and reactive oxygen species formation in rat striatal
1298 synaptosomes are age-dependent. Toxicol. Sci. 87, 156–162.

1299 Duracková, Z., 2010. Some current insights into oxidative stress. Physiol. Res. 59,
1300 459–469.

1301 El-Ashamawy, I.M., Ashry, K.M., El-Nahas, A.F., Salama, O.M., 2006. Protection by
1302 turmeric and myrrh against liver oxidative damage and genotoxicity induced by
1303 lead acetate in mice. Basic Clin. Pharmacol. Toxicol. 98, 32–37.

1304

- 1305 El-Demerdash, F., Yousef, M., Radwan, F., 2009. Ameliorating effect of curcumin on
1306 sodium arsenite-induced oxidative damage and lipid peroxidation in different
1307 rat organs. *Food Chem. Toxicol.* 47, 249–254.
- 1308 El-Newehy, M.S., El-Sayed, Y.S., 2011. Influence of vitamin C supplementation on
1309 lead-induced histopathological alterations in male rats. *Exp. Toxicol. Pathol.* 63,
1310 221–227.
- 1311 El-Sherbiny, M., Araffa, A., Mantawy, M., Hassan, H.M., 2010. Protective role of
1312 curcumin against oxidative stress, immunosuppressive and cytotoxic effects of
1313 lead exposure. *World Appl. Sci. J.* 11, 1557–1562.
- 1314 Endo, H., Sugijoka, Y., Nakagaki, Y., Saijo, Y., Yoshida, T., 2008. A novel role of the Nrf2
1315 transcription factor in the regulation of arsenite-mediated keratin 16 gene
1316 expression in human keratinocytes. *Environ. Health Perspect.* 116, 873–879.
- 1317 Ercal, N., Gurer-Orhan, H., Aykin-Burns, N., 2001. Toxic metals and oxidative stress
1318 part I: mechanisms involved in metal-induced oxidative damage. *Curr. Top.
1319 Med. Chem.* 1, 529–539.
- 1320 Esatbeyoglu, T., Huebbe, P., Ernst, I.M.A., Chin, D., Wagner, A.E., Rimbach, G., 2012.
1321 Curcumin—from molecule to biological function. *Angew. Chem.* 51, 5308–5332.
- 1322 Escobar, J., Varela-Nallar, L., Coddou, C., Nelson, P., Maisey, K., Valdés, D., Aspee, A.,
1323 Espinosa, V., Rozas, C., Montoya, M., Mandiola, C., Rodríguez, F., Acuña-Castillo,
1324 C., Escobar, A., Fernández, R., Diaz, H., Sandoval, M., Imarai, M., Rios, M., 2010.
1325 Oxidative damage in lymphocytes of copper smelter workers correlated to
1326 higher levels of excreted arsenic. *Mediators Inflamm.* 2010, 1–8.
- 1327 Eybl, V., Kotyzová, D., Bludovská, M., 2004. The effect of curcumin on cadmium-
1328 induced oxidative damage and trace elements level in the liver of rats and mice.
1329 *Toxicol. Lett.* 151, 79–85.
- 1330 Eybl, V., Kotyzova, D., Koutensky, J., 2006a. Comparative study of natural
1331 antioxidants – curcumin, resveratrol and melatonin – in cadmium-induced
1332 oxidative damage in mice. *Toxicology* 225, 150–156.
- 1333 Eybl, V., Kotyzová, D., Lesetický, L., Bludovská, M., Koutenský, J., 2006b. The
1334 influence of curcumin and manganese complex of curcumin on cadmium-
1335 induced oxidative damage and trace elements status in tissues of mice. *J. Appl.
1336 Toxicol.* 26, 207–212.
- 1337 Fan, J., Li, X., Yan, Y., Tian, X., Hou, W., Tong, H., Bai, S., 2012. Curcumin attenuates
1338 rat thoracic aortic aneurysm formation by inhibition of the c-Jun N-terminal
1339 kinase pathway and apoptosis. *Nutrition* 28, 1068–1074.
- 1340 FAO, 2004. Chemical and Technical Assessment. 61st JECFA. Food and Agriculture
1341 Organization. <[http://www.fao.org/fileadmin/templates/agns/pdf/jecfa/cta/61/
1342 Curcumin.pdf](http://www.fao.org/fileadmin/templates/agns/pdf/jecfa/cta/61/Curcumin.pdf)>.
- 1343 Farghaly, H., Hussein, M., 2010. Protective effect of curcumin against paracetamol-
1344 induced liver damage. *Aust. J. Basic Appl. Sci.* 4, 4266–4274.
- 1345 Farina, M., Rocha, J., Aschner, M., 2011. Mechanisms of methylmercury-induced
1346 neurotoxicity: evidence from experimental studies. *Life Sci.* 89, 555–563.
- 1347 Farina, M., Avila, D., da Rocha, J., Aschner, M., 2013. Metals, oxidative stress and
1348 neurodegeneration: a focus on iron, manganese and mercury. *Neurochem. Int.*
1349 62, 575–594.
- 1350 Farombi, E.O., Shrotriya, S., Na, H.K., Kim, S.H., Surh, Y.J., 2008. Curcumin attenuates
1351 dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated
1352 induction of heme oxygenase-1. *Food Chem. Toxicol.* 46, 1279–1287.
- 1353 Farzanegi, P., Saberi, S., Fakharian, A., Rasaei, M.J., Roshan, V.D., 2012. Combined
1354 effects of *Curcuma longa* and exercise training on kidney and spleen tissue levels
1355 of glutathione peroxidase and protein carbonyl in rats exposed to lead.
1356 *Pathobiology* 15, 49–62.
- 1357 Fernandes, M., Santos, M., Alpoim, M., Madeira, V., Vicente, J., 2002. Chromium(VI)
1358 interaction with plant and animal mitochondrial bioenergetics: a comparative
1359 study. *J. Biochem. Mol. Toxicol.* 16, 53–63.
- 1360 Ferramola, M.L., Antón, R.I., Anzulovich, A.C., Giménez, M.S., 2011. Myocardial
1361 oxidative stress following sub-chronic and chronic oral cadmium exposure in
1362 rats. *Environ. Toxicol. Pharmacol.* 32, 17–26.
- 1363 Fieten, H., Leegwater, P., Watson, A., Rothuizen, J., 2012. Canine models of copper
1364 toxicosis for understanding mammalian copper metabolism. *Mamm. Genome*
1365 23, 62–75.
- 1366 Flora, S.J., Pande, M., Kannan, G.M., Mehta, A., 2004. Lead induced oxidative stress
1367 and its recovery following co-administration of merlatonin or N-acetylcysteine
1368 during chelation with succimer in male rats. *Cell Mol. Biol.* 50, OL543-OL551.
- 1369 Flora, S.J.S., Bhaduria, S., Kannan, G.M., Singh, N., 2007. Arsenic induced oxidative
1370 stress and the role of antioxidant supplementation during chelation: a review. *J.
1371 Environ. Biol.* 28, 333–347.
- 1372 Flora, S.J., Mittal, M., Mehta, A., 2008. Heavy metal induced oxidative stress & its
1373 possible reversal by chelation therapy. *Indian J. Med. Res.* 128, 501–523.
- 1374 Flora, G., Gupta, D., Tiwari, A., 2012. Toxicity of lead: a review with recent updates.
1375 *Interdiscip. Toxicol.* 5, 47–58.
- 1376 Flora, G., Gupta, D., Tiwari, A., 2013. Preventive efficacy of bulk and nanocurcumin
1377 against lead-induced oxidative stress in mice. *Biol. Trace Elem. Res.* 152, 31–40.
- 1378 Fluharty, A., Sanadi, D., 1962. On the mechanism of oxidative phosphorylation. IV.
1379 Mitochondrial swelling caused by arsenite in combination with 2,3-
1380 dimercaptopropanol and by cadmium ion. *Biochemistry* 1, 276–281.
- 1381 Fouad, A., Al-Mulhim, A., Jresat, I., 2012. Telmisartan treatment attenuates arsenic-
1382 induced hepatotoxicity in mice. *Toxicology* 300, 149–157.
- 1383 Franco, J.L., Posser, T., Dunkley, P.R., Dickson, P.W., Mattos, J.J., Martins, R., Bairy,
1384 A.C.D., Marques, M.R., Dafre, A.L., Farina, M., 2009. Methylmercury neurotoxicity
1385 is associated with inhibition of the antioxidant enzyme glutathione peroxidase.
1386 *Free Radic. Biol. Med.* 47, 449–457.
- 1387 Fujisawa, S., Atsumi, T., Ishihara, M., Kadoma, Y., 2004. Cytotoxicity, ROS-generation
1388 activity and radical scavenging activity of curcumin and related compounds.
1389 *Anticancer Res.* 24, 563–570.
- 1390 Gaetke, L., 2003. Copper toxicity, oxidative stress, and antioxidant nutrients. *1391
1392 Toxicology* 189, 147–163.
- 1393 Gangwar, R.K., Dhumale, V.A., Kumari, D., Nakate, U.T., Gosavi, S.W., Sharma, R.B.,
1394 Kale, S.N., Datar, S., 2012. Conjugation of curcumin with PVP capped gold
1395 nanoparticles for improving bioavailability. *Mater. Sci. Eng. C* 32, 2659–2663.
- 1396 Gao, S., Duan, X., Wang, X., Dong, D., Liu, D., Li, X., Sun, G., Li, B., 2013. Curcumin
1397 attenuates arsenic-induced hepatic injuries and oxidative stress in
1398 experimental mice through activation of Nrf2 pathway, promotion of arsenic
1399 methylation and urinary excretion. *Food Chem. Toxicol.* 59, 739–747.
- 1400 Garcea, G., Jones, D.J.L., Singh, R., Dennison, A.R., Farmer, P.B., Sharma, R.A., Steward,
1401 W.P., Gescher, A.J., Berry, D.P., 2004. Detection of curcumin and its metabolites
1402 in hepatic tissue and portal blood of patients following oral administration. *Br. J.
1403 Cancer* 90, 1011–1015.
- 1404 Garcea, G., Berry, D.P., Jones, D.J.L., Singh, R., Dennison, A.R., Farmer, P.B., Sharma,
1405 R.A., Steward, W.P., Gescher, A.J., 2005. Consumption of the putative
1406 chemopreventive agent curcumin by cancer patients: assessment of curcumin
1407 levels in the colorectum and their pharmacodynamic consequences. *Cancer
1408 Epidemiol. Biomarkers Prev.* 14, 120–125.
- 1409 García-Niño, W.R., Tapia, E., Zazueta, C., Zatarain-Barrón, Z.L., Hernández-Pando, R.,
1410 Vega-García, C.C., Pedraza-Chaverri, J., 2013. Curcumin pretreatment prevents
1411 potassium dichromate-induced hepatotoxicity, oxidative stress, decreased
1412 respiratory complex I activity, and membrane permeability transition pore
1413 opening. *Evid. Based Complement. Altern. Med.* 2013, 424692.
- 1414 Garg, R., Gupta, S., Maru, G.B., 2008. Dietary curcumin modulates transcriptional
1415 regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice:
1416 mechanism of its anti-initiating action. *Carcinogenesis* 29, 1022–1032.
- 1417 Ghatak, S., Biswas, A., Dhali, G., Chowdhury, A., Boyer, J., Santra, A., 2011. Oxidative
1418 stress and hepatic stellate cell activation are key events in arsenic induced liver
1419 fibrosis in mice. *Toxicol. Appl. Pharmacol.* 251, 59–69.
- 1420 Ghoniem, M.H., El-sharkawy, N.I., Hussein, M.M.A., Moustafa, G.G., 2012. Efficacy of
1421 curcumin on lead induced nephrotoxicity in female albino rats. *J. Am. Sci.* 8,
1422 502–510.
- 1423 Gillis, B.S., Arbieve, Z., Gavin, I.M., 2012. Analysis of lead toxicity in human cells.
1424 *BMC Genomics* 13, 344.
- 1425 Giuliadori, M., Ramírez, C., Ayala, M., 1997. Acute copper intoxication after a Cu–Ca
1426 EDTA injection in rats. *Toxicology* 124, 173–177.
- 1427 Goering, P., Fisher, B., Kish, C., 1993. Stress protein synthesis induced in rat liver by
1428 cadmium precedes hepatotoxicity. *Toxicol. Appl. Pharmacol.* 122, 139–148.
- 1429 Gong, C., Deng, S., Wu, Q., Xiang, M., Wei, X., Li, L., Gao, X., Wang, B., Sun, L., Chen, Y.,
1430 Li, Y., Liu, L., Qian, Z., Wei, Y., 2013. Improving antiangiogenesis and anti-tumor
1431 activity of curcumin by biodegradable polymeric micelles. *Biomaterials* 34,
1432 1413–1432.
- 1433 González-Reyes, S., Guzmán-Beltrán, S., Medina-Campos, O.N., Pedraza-Chaverri, J.,
1434 2013. Curcumin pretreatment induces Nrf2 and an antioxidant response and
1435 prevents hemin-induced toxicity in primary cultures of cerebellar granule
1436 neurons of rats. *Oxid. Med. Cell Longev.* 2013, 801418.
- 1437 Gryniewicz, G., Ślifirski, P., 2012. Curcumin and curcuminoids in quest for
1438 medicinal status. *Acta Biochim. Pol.* 59, 201–212.
- 1439 Guha Mazumder, D., 2005. Effect of chronic intake of arsenic-contaminated water
1440 on liver. *Toxicol. Appl. Pharmacol.* 206, 169–175.
- 1441 Gunaratnam, M., Grant, M., 2008. Cr (VI) inhibits DNA, RNA and protein syntheses in
1442 hepatocytes: involvement of glutathione reductase, reduced glutathione and
1443 DT-diaphorase. *Toxicol. In Vitro* 22, 879–886.
- 1444 Guo, Y., Baysal, K., Kang, B., Yang, L., Williamson, J., 1998. Correlation between
1445 sustained c-Jun N-terminal protein kinase activation and apoptosis induced by
1446 tumor necrosis factor-alpha in rat mesangial cells. *J. Biol. Chem.* 273, 4027–
1447 4034.
- 1448 Gupta, S.C., Prasad, S., Kim, J.H., Patchva, S., Webb, L.J., Priyadarsini, I.K., Aggarwal,
1449 B.B., 2011. Multitargeting by curcumin as revealed by molecular interaction
1450 studies. *Nat. Prod. Rep.* 28, 1937–1955.
- 1451 Gupta, S.C., Patchva, S., Aggarwal, B.B., 2013. Therapeutic roles of curcumin: lessons
1452 learned from clinical trials. *AAPS J.* 15, 195–218.
- 1453 Gurer, H., Ercal, N., 2000. Can antioxidants be beneficial in the treatment of lead
1454 poisoning? *Free Radic. Biol. Med.* 29, 927–945.
- 1455 Gutierrez, L., Mazzotti, N., Araújo, A., Klipel, R., Fernandes, T., Llesuy, S., Belló-Klein,
1456 A., 2006. Peripheral markers of oxidative stress in chronic mercuric chloride
1457 intoxication. *Braz. J. Med. Biol. Res.* 39, 767–772.
- 1458 Habeebu, S., Liu, J., Klaassen, C., 1998. Cadmium-induced apoptosis in mouse liver.
1459 *Toxicol. Appl. Pharmacol.* 149, 203–209.
- 1460 Hao, L., Zhao, J., Wang, X., Wang, H., Xu, G., 2013. Hepatotoxicity from arsenic
1461 trioxide for pediatric acute promyelocytic leukemia. *J. Pediatr. Hematol. Oncol.*
1462 35, e67–e70.
- 1463 Hare, M.F., Atchison, W.D., 1992. Comparative action of methylmercury and
1464 divalent inorganic mercury on nerve terminal and intraterminal
1465 mitochondrial membrane potentials. *J. Pharmacol. Exp. Ther.* 261, 166–172.
- 1466 He, X., Chen, M.G., Lin, G.X., Ma, Q., 2006. Arsenic induces NAD(P)H-quinone
1467 oxidoreductase I by disrupting the Nrf2-Keap1-Cul3 complex and recruiting
1468 Nrf2-Maf to the antioxidant response element enhancer. *J. Biol. Chem.* 281,
1469 23620–23631.
- 1470 He, X., Lin, G.X., Chen, M.G., Zhang, J.X., Ma, Q., 2007. Protection against chromium
1471 (VI)-induced oxidative stress and apoptosis by Nrf2. Recruiting Nrf2 into the
1472 nucleus and disrupting the nuclear Nrf2/Keap1 association. *Toxicol. Sci.* 98,
1473 298–309.
- 1474 He, X., Chen, M.G., Ma, Q., 2008. Activation of Nrf2 in defense against cadmium-
1475 induced oxidative stress. *Chem. Res. Toxicol.* 21, 1375–1383.

1475 Hébert, C., Elwell, M., Travlos, G., Fitz, C., Bucher, J., 1993. Subchronic toxicity of
 1476 cupric sulfate administered in drinking water and feed to rats and mice.
 1477 *Fundam. Appl. Toxicol.* 21, 461–475.

1478 Hemeida, R., Mohafez, O., 2008. Curcumin attenuates methotrexate-induced
 1479 hepatic oxidative damage in rats. *J. Egypt Natl. Cancer Inst.* 20, 141–148.

1480 Henke, D.C., 2008. Cystic fibrosis bench to bedside for *Curcuma longa* L. in cystic
 1481 fibrosis – Curcumin’s controversial role as therapy. *US Respir. Dis.* 4, 76–78.

1482 Henkler, F., Brinkmann, J., Luch, A., 2010. The role of oxidative stress in
 1483 carcinogenesis induced by metals and xenobiotics. *Cancers (Basel)* 2, 376–396.

1484 Hernández-Esquivel, L., Zazueta, C., Buena-Chontal, M., Hernández-Reséndiz, S.,
 1485 Pavón, N., Chávez, E., 2011. Protective behavior of tamoxifen against Hg²⁺-
 1486 induced toxicity on kidney mitochondria: in vitro and in vivo experiments. *J.*
 1487 *Steroid Biochem. Mol. Biol.* 127, 345–350.

1488 Hernández-Franco, P., Silva, M., Valverde, M., Rojas, E., 2011. Induction of oxidative
 1489 stress by low doses of lead in human hepatic cell line WRL-68. *Biometals* 24,
 1490 951–958.

1491 Hogstad, O., 1996. Accumulation of cadmium, copper and zinc in the liver of some
 1492 passerine species wintering in central Norway. *Sci. Total Environ.* 183, 187–194.

1493 Holt, P.R., Katz, S., Kirshoff, R., 2005. Curcumin therapy in inflammatory bowel
 1494 disease: a pilot study. *Dig. Dis. Sci.* 50, 2191–2193.

1495 Hong, F., Sekhar, K.R., Freeman, M.L., Liebler, D.C., 2005. Specific patterns of
 1496 electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. *J. Biol.*
 1497 *Chem.* 280, 31768–31775.

1498 Hossain, K., Akhand, A.A., Kato, M., Du, J., Takeda, K., Wu, J., Takeuchi, K., Liu, W.,
 1499 Suzuki, H., Nakashima, I., 2000. Arsenite induces apoptosis of murine T
 1500 lymphocytes through membrane raft-linked signaling for activation of c-Jun
 1501 amino-terminal kinase. *J. Immunol.* 165, 4290–4297.

1502 Hosseini, M., Shaki, F., Ghazi-Khansari, M., Pouhramad, J., 2013. Toxicity of arsenic
 1503 (III) on isolated liver mitochondria: a new mechanistic approach. *Iran. J. Pharm.*
 1504 *Res.* 12, 121–138.

1505 Hsu, C., Cheng, A., 2007. Clinical studies with curcumin. *Adv. Exp. Med. Biol.* 595,
 1506 471–480.

1507 Huang, Y.L., Cheng, S.L., Lin, T.H., 1996. Lipid peroxidation in rats administered with
 1508 mercuric chloride. *Biol. Trace Elem. Res.* 52, 193–206.

1509 Huang, H.-C., Nguyen, T., Pickett, C.B., 2002. Phosphorylation of Nrf2 at Ser-40 by
 1510 protein kinase C regulates antioxidant response element-mediated
 1511 transcription. *J. Biol. Chem.* 277, 42769–42774.

1512 Huang, Y., Chao, K.S.C., Liao, H., Chen, Y., 2013. Targeting sonic hedgehog signaling
 1513 by compounds and derivatives from natural products. *Evid.-Based Complement.*
 1514 *Altern. Med.* 2013, 748587.

1515 Hultberg, B., Andersson, A., Isaksson, A., 1998. Alterations of thiol metabolism in
 1516 human cell lines induced by low amounts of copper, mercury or cadmium ions.
 1517 *Toxicology* 126, 203–212.

1518 Hultberg, B., Andersson, A., Isaksson, A., 2001. Interaction of metals and thiols in cell
 1519 damage and glutathione distribution: potentiation of mercury toxicity by
 1520 dithiothreitol. *Toxicology* 156, 93–100.

1521 Humphrey, M.L., Cole, M.P., Pendergrass, J.C., Kinningham, K.K., 2005. Mitochondrial
 1522 mediated thimerosal-induced apoptosis in a human neuroblastoma cell line
 1523 (SK-N-SH). *Neurotoxicology* 26, 407–416.

1524 Hussain, S., Atkinson, A., Thompson, S.J., Khan, A.T., 1999. Accumulation of mercury
 1525 and its effect on antioxidant enzymes in brain, liver, and kidneys of mice. *J.*
 1526 *Environ. Sci. Health* 34, 645–660.

1527 Hyder, O., Chung, M., Cosgrove, D., Jm, H., Li, Z., Firoozmand, A., Gurakar, A., Pawlik,
 1528 T., 2013. Cadmium exposure and liver disease among US adults. *J. Gastrointest.*
 1529 *Surg.* 17, 1265–1273.

1530 Iqbal, M., Sharma, S., Okazaki, Y., Fujisawa, M., Okada, S., 2003. Dietary
 1531 supplementation of curcumin enhances antioxidant and phase II metabolizing
 1532 enzymes in ddY male mice: possible role in protection against chemical
 1533 carcinogenesis and toxicity. *Pharmacol. Toxicol.* 92, 33–38.

1534 Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S.,
 1535 Yamamoto, M., 2000. Transcription factor Nrf2 coordinately regulates a group of
 1536 oxidative stress-inducible genes in macrophages. *J. Biol. Chem.* 275, 16023–
 1537 16029.

1538 IUPAC, 2002. “Heavy metals” – a meaningless term? (IUPAC Technical Report). *Pure*
 1539 *Appl. Chem.* 74, 793–807.

1540 Jaffe, E.K., Martins, J., Li, J., Kervinen, J., Dunbrack, R.L., 2001. The molecular
 1541 mechanism of lead inhibition of human porphobilinogen synthase. *J. Biol.*
 1542 *Chem.* 276, 1531–1537.

1543 James, J.S., 1994. Curcumin trial results: antiviral effect reported. *AIDS Treat. News*
 1544 198, 1.

1545 Jannetto, P., Antholine, W., Myers, C., 2001. Cytochrome b(5) plays a key role in
 1546 human microsomal chromium(VI) reduction. *Toxicology* 159, 119–133.

1547 Jarrar, B.M., Taib, N.T., 2012. Histological and histochemical alterations in the liver
 1548 induced by lead chronic toxicity. *Saudi J. Biol. Sci.* 19, 203–210.

1549 Jarup, L., 2003. Hazards of heavy metal contamination. *Br. Med. Bull.* 68, 167–182.

1550 Jeong, G.S., Oh, G.S., Pae, H.-O., Jeong, S.-O., Kim, Y.-C., Shin, M.-K., Seo, B.Y., Han, S.Y.,
 1551 Lee, H.S., Jeong, J.-G., Koh, J.-S., Chung, H.-T., 2006. Comparative effects of
 1552 curcuminoids on endothelial heme oxygenase-1 expression: ortho-methoxy
 1553 groups are essential to enhance heme oxygenase activity and protection. *Exp.*
 1554 *Mol. Med.* 38, 393–400.

1555 Jiang, T., Huang, Z., Chan, J.Y., Zhang, D.D., 2009. Nrf2 protects against As(III)-induced
 1556 damage in mouse liver and bladder. *Toxicol. Appl. Pharmacol.* 240, 8–14.

1557 Joe, B., Lokesh, B.R., 1994. Role of capsaicin, curcumin and dietary n-3 fatty acids in
 1558 lowering the generation of reactive oxygen species in rat peritoneal
 1559 macrophages. *Biochim. Biophys. Acta* 1224, 255–263.

Jomova, K., Valko, M., 2011. Advances in metal-induced oxidative stress and human
 1560 disease. *Toxicology* 283, 65–87.

Jomova, K., Jenisova, Z., Feszterova, M., Baros, S., Liska, J., Hudecova, D., Rhodes, C.J.,
 1561 Valko, M., 2011. Arsenic: toxicity, oxidative stress and human disease. *J. Appl.*
 1562 *Toxicol.* 31, 95–107.

Joshi, D., Mittal, D., Shrivastav, S., Shukla, S., Srivastav, A., 2011. Combined effect of
 1563 N-acetyl cysteine, zinc, and selenium against chronic dimethylmercury-induced
 1564 oxidative stress: a biochemical and histopathological approach. *Arch. Environ.*
 1565 *Contam. Toxicol.* 61, 558–567.

Joshi, D., Mittal, D., Shukla, S., Srivastav, A., 2012. Therapeutic potential of N-acetyl
 1566 cysteine with antioxidants (Zn and Se) supplementation against
 1567 dimethylmercury toxicity in male albino rats. *Exp. Toxicol. Pathol.* 64, 103–108.

Jovanovic, S.V., Steenken, S., Boone, C.W., Simic, M.G., 1999. H-atom transfer is a
 1568 preferred antioxidant mechanism of curcumin. *J. Am. Chem. Soc.* 121, 9677–
 1569 9681.

Jurczuk, M., Moniuszko-Jakoniuk, J., Rogalska, J., 2006. Evaluation of oxidative stress
 1570 in hepatic mitochondria of rats exposed to cadmium and ethanol. *Polish J.*
 1571 *Environ. Stud.* 15, 853–860.

Jurenka, J., 2009. Anti-inflammatory properties of curcumin, a major constituent of
 1572 *Curcuma longa*: a review of preclinical and clinical research. *Altern. Med. Rev.*
 1573 14, 141–153.

Kalahasthi, R., Rao, R., Murthy, R., Kumar, M., 2006. Effect of chromium(VI) on the
 1574 status of plasma lipid peroxidation and erythrocyte antioxidant enzymes in
 1575 chromium plating workers. *Chem. Biol. Interact.* 164, 192–199.

Kalayarasan, S., Sriram, N., Sureshkumar, A., Sudhandiran, G., 2008. Chromium (VI)-
 1576 induced oxidative stress and apoptosis is reduced by garlic and its derivative S-
 1577 allylcysteine through the activation of Nrf2 in the hepatocytes of Wistar rats. *J.*
 1578 *Appl. Toxicol.* 28, 908–919.

Kang, K.W., Ryu, J.H., Kim, S.G., 2000. The essential role of phosphatidylinositol 3-
 1579 kinase and of p38 mitogen-activated protein kinase activation in the
 1580 antioxidant response element-mediated rGSTA2 induction by decreased
 1581 glutathione in H4IIE hepatoma cells. *Mol. Pharmacol.* 58, 1017–1025.

Kang, E.S., Kim, G.H., Kim, H.J., Woo, I.S., Ham, S.A., Jin, H., Kim, M.Y., Lee, J.H., Chang,
 1582 K.C., Seo, H.G., Hwang, J.Y., 2008. Nrf2 regulates curcumin-induced aldose
 1583 reductase expression indirectly via nuclear factor-kappaB. *Pharmacol. Res.* 58,
 1584 15–21.

Kang, M., Cho, S., Lim, Y., Seo, J., Hong, Y., 2013. Effects of environmental cadmium
 1585 exposure on liver function in adults. *Occup. Environ. Med.* 70, 268–273.

Kanluen, S., Gottlieb, C.A., 1991. A clinical pathologic study of four adult cases of
 1586 acute mercury inhalation toxicity. *Arch. Pathol. Lab. Med.* 115, 56–60.

Kaspar, J.W., Niture, S.K., Jaiswal, A.K., 2009. Nrf 2: Nrf2 (Keap1) signaling in
 1587 oxidative stress. *Free Radic. Biol. Med.* 47, 1304–1309.

Kensler, T.W., Wakabayashi, N., Biswal, S., 2007. Cell survival responses to
 1588 environmental stresses via the Keap1-Nrf2-ARE pathway. *Annu. Rev.*
 1589 *Pharmacol. Toxicol.* 47, 89–116.

Khan, S., Ja, V., Su, N., Gupta, G., Kumar, D., Ag, T., Jk, M., 2012. Protective effect of
 1590 curcumin against arsenic-induced apoptosis in murine splenocytes in vitro. *J.*
 1591 *Immunotoxicol.* 9, 148–159.

Khan, S., Telang, A., Malik, J., 2013. Arsenic-induced oxidative stress, apoptosis and
 1592 alterations in testicular steroidogenesis and spermatogenesis in wistar rats:
 1593 ameliorative effect of curcumin. *Wudpecker J. Pharm. Pharmacol.* 2, 33–48.

Kidd, P.M., 2009. Bioavailability and activity of phytosome complexes from
 1594 botanical polyphenols: the silymarin, curcumin, green tea, and grape seed
 1595 extracts. *Altern. Med. Rev.* 14, 226–246.

Kim, S., Sharma, R., 2004. Mercury-induced apoptosis and necrosis in murine
 1596 macrophages: role of calcium-induced reactive oxygen species and p38
 1597 mitogen-activated protein kinase signaling. *Toxicol. Appl. Pharmacol.* 196,
 1598 47–57.

Kim, M., Kim, B., Woo, H., Kim, K., Kim, K., Kim, I., Jung, Y., 2000. Cadmium induces
 1599 caspase-mediated cell death: suppression by Bcl-2. *Toxicology* 145, 27–37.

Kim, D.H., Phillips, J.F., Lockey, R.F., 2011. Oral curcumin supplementation in
 1600 patients with atopic asthma. *Allergy Rhinol.* 2, e51–e53.

Kim, S., Ha, K., Choi, E., Jung, S., Kim, M., Kwon, D., Yang, H., Kim, M., Kang, H., Back,
 1601 H., Kim, S., Park, S., Baek, H., Kim, Y., Lee, J., Chae, S., 2013. The effectiveness of
 1602 fermented turmeric powder in subjects with elevated alanine transaminase
 1603 levels: a randomised controlled study. *BMC Complement. Altern. Med.* 13, 58.

Klaassen, C., Liu, J., Diwan, B., 2009. Metallothionein protection of cadmium toxicity.
 1604 *Toxicol. Appl. Pharmacol.* 238, 215–220.

Kojima, M., Masui, T., Nemoto, K., Degawa, M., 2004. Lead nitrate-induced
 1605 development of hypercholesterolemia in rats: sterol-independent gene
 1606 regulation of hepatic enzymes responsible for cholesterol homeostasis.
 1607 *Toxicol. Lett.* 154, 35–44.

Kong, A.N., Owuor, E., Yu, R., Hebbar, V., Chen, C., Hu, R., Mandekar, S., 2001.
 1608 Induction of xenobiotic enzymes by the MAP kinase pathway and the
 1609 antioxidant or electrophile response element (ARE/EpRE). *Drug Metab. Rev.*
 1610 33, 255–271.

Korashy, H.M., El-Kadi, A.O.S., 2006. Transcriptional regulation of the
 1611 NAD(P)H:quinone oxidoreductase 1 and glutathione S-transferase Ya genes
 1612 by mercury, lead, and copper. *Drug Metab. Dispos.* 34, 152–165.

Korashy, H.M., El-Kadi, A.O.S., 2012. Transcriptional and posttranslational
 1613 mechanisms modulating the expression of the cytochrome P450 1A1 gene by
 1614 lead in HepG2 cells: a role of heme oxygenase. *Toxicology* 291, 113–121.

Kou, M.C., Chiou, S.Y., Weng, C.Y., Wang, L., Ho, C.T., Wu, M.J., 2013. Curcuminoids
 1615 distinctly exhibit antioxidant activities and regulate expression of scavenger
 1616 receptors and heme oxygenase-1. *Mol. Nutr. Food Res.* 57, 1598–1610.

- Kuester, R., Waalkes, M., Goering, P., Fisher, B., McCuskey, R., Sipes, I., 2002. Differential hepatotoxicity induced by cadmium in Fischer 344 and Sprague-Dawley rats. *Toxicol. Sci.* 65, 151–159.
- Kumar, K., Maliakel, B.P., 2007. Curcumin: a natural yellow pigment with great potential. *AgroFood Ind. Hi-Tech* 18, 52–53.
- Kurd, S.K., Smith, N., VanVoorhees, A., Troxel, A.B., Badmaev, V., Seykora, J.T., Gelfand, J.M., 2008. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. *J. Am. Acad. Dermatol.* 58, 625–631.
- Kurosaki, K., Nakamura, T., Mukai, T., Endo, T., 1995. Unusual findings in a fatal case of poisoning with chromate compounds. *Forensic Sci. Int.* 75, 57–65.
- Kutluay, S.B., Doroghazi, J., Roemer, M.E., Triezenberg, S.J., 2008. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. *Virology* 373, 239–247.
- Lake, L., Gerschenson, L.E., 1978. Cellular and molecular toxicology of lead. III Effect of lead on heme synthesis. *J. Toxicol. Environ. Health* 4, 527–540.
- Lal, B., Kapoor, A.K., Asthana, O.P., Agrawal, P.K., Prasad, R., Kumar, P., Srimal, R.C., 1999. Efficacy of curcumin in the management of chronic anterior uveitis. *Phytother. Res.* 13, 318–322.
- Lao, C.D., Ruffin, M.T., Normolle, D., Heath, D.D., Murray, S.I., Bailey, J.M., Boggs, M.E., Crowell, J., Rock, C.L., Brenner, D.E., 2006. Dose escalation of a curcuminoid formulation. *BMC Complement. Altern. Med.* 6, 10.
- Leffler, P., Jin, T., Nordberg, G., 2000. Differential calcium transport disturbances in renal membrane vesicles after cadmium-metallothionein injection in rats. *Toxicology* 143, 227–234.
- Li, M., Xia, T., Jiang, C., Li, L., Fu, J., Zhou, Z., 2003. Cadmium directly induced the opening of membrane permeability pore of mitochondria which possibly involved in cadmium-triggered apoptosis. *Toxicology* 194, 19–33.
- Li, D., An, D., Zhou, Y., Liu, J., Waalkes, M.P., 2006. Current status and prevention strategy for coal-arsenic poisoning in Guizhou, China. *J. Health Popul. Nutr.* 24, 273–276.
- Li, B., Li, X., Zhang, X., Zhu, B., Liu, D., Xing, X., Wang, X., Ma, Y., Sun, G., 2011. Effects of inorganic arsenic on mRNA expression of Nrf2 and Nrf2-regulated downstream anti-oxidant enzymes in Chang hepatocytes. *J. Hyg. Res.* 40, 468–471.
- Limke, T., Atchison, W., 2002. Acute exposure to methylmercury opens the mitochondrial permeability transition pore in rat cerebellar granule cells. *Toxicol. Appl. Pharmacol.* 178, 52–61.
- Lin, T.H., Huang, Y.L., Huang, S.F., 1996. Lipid peroxidation in liver of rats administered with methyl mercuric chloride. *Biol. Trace Elem. Res.* 54, 33–41.
- Lin, C., Lin, H., Chen, H., Yu, M., Lee, M., 2009. Stability and characterisation of phospholipid-based curcumin-encapsulated microemulsions. *Food Chem.* 116, 923–928.
- Lin, X., Ji, S., Li, R., Dong, Y., Qiao, X., Hu, H., Yang, W., Guo, D., Tu, P., Ye, M., 2012. Terpecurcumins A-I from the rhizomes of *Curcuma longa*: absolute configuration and cytotoxic activity. *J. Nat. Prod.* 75, 2121–2131.
- Liu, K., Shi, X., 2001. In vivo reduction of chromium (VI) and its related free radical generation. *Mol. Cell. Biochem.* 222, 41–47.
- Liu, J., Waalkes, M., 2008. Liver is a target of arsenic carcinogenesis. *Toxicol. Sci.* 105, 24–32.
- Liu, J., Zheng, B., Aposhian, H., Zhou, Y., Chen, M., Zhang, A., Waalkes, M., 2002. Chronic arsenic poisoning from burning high-arsenic-containing coal in Guizhou, China. *Environ. Health Perspect.* 110, 119–122.
- Liu, J., Benbrahim-Tallaa, L., Qian, X., Yu, L., Xie, Y., Boos, J., Qu, W., Waalkes, M., 2006. Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells. *Toxicol. Appl. Pharmacol.* 216, 407–415.
- Liu, C.-M., Ma, J.-Q., Sun, Y.-Z., 2011. Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats. *Food Chem. Toxicol.* 49, 3119–3127.
- Liu, J., Xu, L., Liu, C., Zhang, D., Wang, S., Deng, Z., Lou, W., Xu, H., Bai, Q., Ma, J., 2012. Preparation and characterization of cationic curcumin nanoparticles for improvement of cellular uptake. *Carbohydr. Polym.* 90, 16–22.
- Liu, D., Duan, X., Dong, D., Bai, C., Li, X., Sun, G., Li, B., 2013a. Activation of the Nrf2 pathway by inorganic arsenic in human hepatocytes and the role of transcriptional repressor Bach1. *Oxid. Med. Cell. Longev.* 2013, 984546.
- Liu, L., Sun, L., Wu, Q., Guo, W., Li, L., Chen, Y., Li, Y., Gong, C., Qian, Z., Wei, Y., 2013b. Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis. *Int. J. Pharm.* 443, 175–182.
- Lobo, V., Patil, A., Phatak, A., Chandra, N., 2010. Free radicals, antioxidants and functional foods: Impact on human health. *Pharmacogn. Rev.* 4, 118–126.
- Lu, T., Liu, J., LeCluyse, E.L., Zhou, Y.S., Cheng, M.L., Waalkes, M.P., 2001. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. *Toxicol. Sci.* 59, 185–192.
- Luza, S., Speisky, H., 1996. Liver copper storage and transport during development: implications for cytotoxicity. *Am. J. Clin. Nutr.* 63, 812S–820S.
- Mahboob, M., Shireen, K.F., Atkinson, A., Khan, A.T., 2001. Lipid peroxidation and antioxidant enzyme activity in different organs of mice exposed to low level of mercury. *J. Environ. Sci. Health* 36, 687–697.
- Martelli, A., Rousselet, E., Dyck, C., Bouron, A., Moulis, J., 2006. Cadmium toxicity in animal cells by interference with essential metals. *Biochimie* 88, 1807–1814.
- Martinez-Zamudio, R., Ha, H., 2011. Environmental epigenetics in metal exposure. *Epigenetics* 6, 820–827.
- Mathews, V., Binu, P., Sauganth-Paul, M., Abhilash, M., Manju, A., Nair, R., 2012. Hepatoprotective efficacy of curcumin against arsenic trioxide toxicity. *Asian Pacific J. Trop. Biomed.* 2, S706–S711.
- Mathuria, N., Verma, R., 2007. Curcumin ameliorates aflatoxin-induced lipid peroxidation in liver, kidney and testis of mice – an in vitro study. *Acta Pol. Pharm.* 63, 413–416.
- McKenna, I.M., Bare, R.M., Waalkes, M.P., 1996. Metallothionein gene expression in testicular interstitial cells and liver of rats treated with cadmium. *Toxicology* 107, 121–130.
- Mehana, E.E., Meki, A.R.M.A., Fazili, K.M., 2012. Ameliorated effects of green tea extract on lead induced liver toxicity in rats. *Exp. Toxicol. Pathol.* 64, 291–295.
- Memarmoghaddam, M.M., Roshan, V.D., Hedayati, M., 2011. Effects of lead acetate, endurance training and curcumin supplementation on heat shock protein levels in liver tissue. *Iran. J. Endocrinol. Metab.* 13, 74–81.
- Messarah, M., Amamra, W., Boumendjel, A., Barkat, L., Bouasla, I., Abdenour, C., Boulakoud, M., Feki, A., 2013. Ameliorating effects of curcumin and vitamin E on diazinon-induced oxidative damage in rat liver and erythrocytes. *Toxicol. Ind. Health* 29, 77–88.
- Messner, D.J., Sivam, G., Kowdley, K.V., 2010. Curcumin reduces the toxic effects of iron loading in rat liver epithelial cells. *Liver Int.* 29, 63–72.
- Miller, D.M., Lund, B.O., Woods, J.S., 1991. Reactivity of Hg(II) with superoxide: evidence for the catalytic dismutation of superoxide by Hg(II). *J. Biochem. Toxicol.* 6, 293–298.
- Molina-Jijón, E., Tapia, E., Zazueta, C., El Hafidi, M., Zatarain-Barrón, Z., Hernández-Pando, R., Medina-Campos, O., Zarco-Márquez, G., Torres, I., Pedraza-Chaverri, J., 2011. Curcumin prevents Cr(VI)-induced renal oxidant damage by a mitochondrial pathway. *Free Radic. Biol. Med.* 51, 1543–1557.
- Motohashi, H., Yamamoto, M., 2004. Nrf2-Keap1 defines a physiologically important stress response mechanism. *Trends Mol. Med.* 10, 549–557.
- Motohashi, H., O'Connor, T., Katsuoka, F., Engel, J.D., Yamamoto, M., 2002. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. *Gene* 294, 1–12.
- Mukherjee, S., Roy, M., Dey, S., Bhattacharya, R., 2007. A mechanistic approach for modulation of arsenic toxicity in human lymphocytes by curcumin, an active constituent of medicinal herb *Curcuma longa* linn. *J. Clin. Biochem. Nutr.* 41, 32–42.
- Mukherjee, S., Chatterjee, S., Sarkar, S., Agarwal, S., Kundu, R., Maitra, S., Bhattacharya, S., 2013. Mollusc C-reactive protein crosses species barrier and reverses hepatotoxicity of lead in rodent models. *Indian J. Exp. Biol.* 51, 623–634.
- Muller, P., van Bakel, H., van de Sluis, B., Holstege, F., Wijmenga, C., Klomp, L.W.J., 2007. Gene expression profiling of liver cells after copper overload in vivo and in vitro reveals new copper-regulated genes. *J. Biol. Inorg. Chem.* 12, 495–507.
- Myers, J., Antholine, W., Myers, C., 2008. Hexavalent chromium causes the oxidation of thioredoxin in human bronchial epithelial cells. *Toxicology* 246, 222–233.
- Myers, C.R., Antholine, W.E., Myers, J.M., 2010. The pro-oxidant chromium(VI) inhibits mitochondrial complex I, complex II, and aconitase in the bronchial epithelium: EPR markers for Fe-S proteins. *Free Radic. Biol. Med.* 49, 1903–1915.
- Myers, J., Antholine, W., Myers, C., 2011. The intracellular redox stress caused by hexavalent chromium is selective for proteins that have key roles in cell survival and thiol redox control. *Toxicology* 281, 37–47.
- Nagano, T., Oyama, Y., Kajita, N., Chikahisa, L., Nakata, M., Okazaki, E., Masuda, T., 1997. New curcuminoids isolated from *Zingiber cassumunar* protect cells suffering from oxidative stress: a flow-cytometric study using rat thymocytes and H₂O₂. *Jpn. J. Pharmacol.* 75, 363–370.
- Nakatani, T., Spolter, L., Kobayashi, K., 1994. Redox state in liver mitochondria in acute copper sulfate poisoning. *Life Sci.* 54, 967–974.
- Nandi, D., Patra, R., Swarup, D., 2005. Effect of cysteine, methionine, ascorbic acid and thiamine on arsenic-induced oxidative stress and biochemical alterations in rats. *Toxicology* 211, 26–35.
- Narayana, K., Al-Bader, M., 2011. Ultrastructural and DNA damaging effects of lead nitrate in the liver. *Exp. Toxicol. Pathol.* 63, 43–51.
- NCI, 1996. National Cancer Institute. Clinical development plan – curcumin. *J. Cell. Biochem.* 26S, 72–85.
- Negrette-Guzmán, M., Huerta-Yepez, S., Medina-Campos, O.N., Zatarain-Barrón, Z.L., Hernández-Pando, R., Torres, I., Tapia, E., Pedraza-Chaverri, J., 2013. Sulfaphane attenuates gentamicin-induced nephrotoxicity: role of mitochondrial protection. *Evid.-Based Complement. Altern. Med.* 2013, 135314.
- Nevens, F., Fevery, J., Van Steenberghe, W., Sciot, R., Desmet, V., De Groote, J., 1990. Arsenic and non-cirrhotic portal hypertension. A report of eight cases. *J. Hepatol.* 11, 80–85.
- NIH, 2007. Phase III trial of gemcitabine, curcumin and celebrex in patients with advance or inoperable pancreatic cancer. Clinical Trial.gov identifier: NCT00486460. National Institutes of health (<<http://www.clinicaltrials.gov/ct2/results?term=>curcumin>> last access).
- Nobuntou, W., Parkpian, P., Oanh, N.T., Noomhorm, A., Delaune, R.D., Jugsujinda, A., 2010. Lead distribution and its potential risk to the environment: lesson learned from environmental monitoring of abandon mine. *J. Environ. Sci. Health* 45, 1702–1714.
- Oetari, S., Sudibyo, M., Commandeur, J.N., Samhoedi, R., Vermeulen, N.P., 1996. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. *Biochem. Pharmacol.* 51, 39–45.

1813 Oguzturk, H., Ciftci, O., Aydin, M., Timurkaan, N., Beytur, A., Yilmaz, F., 2012. Ameliorative effects of curcumin against acute cadmium toxicity on male reproductive system in rats. *Andrologia* 44, 243–249.

1814

1815 O'Hara, K.A., Nemeç, A.A., Alam, J., Klei, L.R., Mossman, B.T., Barchowsky, A., 2006. Chromium (VI) inhibits heme oxygenase-1 expression in vivo and in arsenic-exposed human airway epithelial cells. *J. Cell. Physiol.* 209, 113–121.

1816

1817 Ohrvik, H., Oskarsson, A., Lundh, T., Skerfving, S., Tallkvist, J., 2007. Impact of iron status on cadmium uptake in suckling piglets. *Toxicology* 240, 15–24.

1818

1819 Pagliara, P., Carlà, E.C., Caforio, S., Chionna, A., Massa, S., Abbro, L., Dini, L., 2003. Kupffer cells promote lead nitrate-induced hepatocyte apoptosis via oxidative stress. *Comp. Hepatol.* 2, 8.

1820

1821 Pal, M., Ghosh, M., 2012. Studies on comparative efficacy of α -linolenic acid and α -eleostearic acid on prevention of organic mercury-induced oxidative stress in kidney and liver of rat. *Food Chem. Toxicol.* 50, 1066–1072.

1822

1823 Pal, P.B., Sinha, K., Sil, P.C., 2013. Mangiferin, a natural xanthone, protects murine liver in Pb(II) induced hepatic damage and cell death via MAP kinase, NF- κ B and mitochondria dependent pathways. *PLoS One* 8, e56894.

1824

1825 Pan, X., Dai, Y., Li, X., Niu, N., Li, W., Liu, F., Zhao, Y., Yu, Z., 2011. Inhibition of arsenic-induced rat liver injury by grape seed extract through suppression of NADPH oxidase and TGF- β /Smad activation. *Toxicol. Appl. Pharmacol.* 254, 323–331.

1826

1827 Pandya, C.D., Pillai, P.P., Gupta, S.S., 2010. Lead and cadmium co-exposure mediated toxic insults on hepatic steroid metabolism and antioxidant system of adult male rats. *Biol. Trace Elem. Res.* 134, 307–317.

1828

1829 Pantazis, P., Varman, A., Simpson-Durand, C., Thorpe, J., Ramalingam, S., Subramaniam, D., Houchen, C., Ilnat, M., Anant, S., Ramanujam, R.P., 2010. Curcumin and turmeric attenuate arsenic-induced angiogenesis in ovo. *Altern. Ther. Health Med.* 16, 12–14.

1830

1831 Park, J.Y., Seo, Y.R., 2011. The protective role of Nrf2 in cadmium-induced DNA damage. *Mol. Cell. Toxicol.* 7, 61–66.

1832

1833 Park, J.D., Liu, Y., Klaassen, C.D., 2001. Protective effect of metallothionein against the toxicity of cadmium and other metals. *Toxicology* 163, 93–100.

1834

1835 Pathak, N., Khandelwal, S., 2008. Comparative efficacy of piperine, curcumin and picrolic acid against Cd immunotoxicity in mice. *Biomaterials* 21, 649–661.

1836

1837 Patil, A.J., Bhagwat, V.R., Patil, J.A., Dongre, N.N., Ambekar, J.G., Jaikhan, R., Das, K.K., 2006. Effect of lead (Pb) exposure on the activity of superoxide dismutase and catalase in battery manufacturing workers (BMW) of Western Maharashtra (India) with reference to heme biosynthesis. *Int. J. Environ. Res. Public Health* 3, 329–337.

1838

1839 Patlolla, A.K., Barnes, C., Yedjou, C., Velma, V., Tchounwou, P., 2009. Oxidative stress, DNA damage, and antioxidant enzyme activity induced by hexavalent chromium in Sprague-Dawley rats. *Environ. Toxicol.* 24, 66–73.

1840

1841 Patra, R., Rautray, A., Swarup, D., 2011. Oxidative stress in lead and cadmium toxicity and its amelioration. *Vet. Med. Int.* 2011, 457327.

1842

1843 Patrick, L., 2006. Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. *Altern. Med. Rev.* 11, 114–127.

1844

1845 Peña, M., Lee, J., Thiele, D., 1999. A delicate balance: homeostatic control of copper uptake and distribution. *J. Nutr.* 129, 1251–1260.

1846

1847 Pérez-De La Cruz, V., González-Cortés, C., Pedraza-Chaverrí, J., Maldonado, P.D., Andrés-Martínez, L., Santamaría, A., 2006. Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. *Brain Res. Bull.* 68, 379–383.

1848

1849 Pi, J., Qu, W., Reece, J.M., Kumagai, Y., Waalkes, M.P., 2003. Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. *Exp. Cell Res.* 290, 234–245.

1850

1851 Piper, J.T., Singhal, S.S., Salameh, M.S., Torman, T., Awasthi, Y.C., Awasthi, S., 1998. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. *Int. J. Biochem. Cell Biol.* 30, 445–456.

1852

1853 Piret, J.P., Jacques, D., Audinot, J.N., Mejia, J., Boilan, E., Noël, F., Fransolet, M., Demazy, C., Lucas, S., Saout, C., Toussaint, O., 2012. Copper (II) oxide nanoparticles penetrate into HepG2 cells, exert cytotoxicity via oxidative stress and induce pro-inflammatory response. *Nanoscale* 4, 7168–7184.

1854

1855 Polunas, M., Halladay, A., Tjalkens, R.B., Philbert, M., Lowndes, H., Reuhl, K., 2011. Role of oxidative stress and the mitochondrial permeability transition in methylmercury cytotoxicity. *Neurotoxicology* 32, 526–534.

1856

1857 Pourahmad, J., O'Brien, P., 2000. A comparison of hepatocyte cytotoxic mechanisms for Cu²⁺ and Cd²⁺. *Toxicology* 143, 263–273.

1858

1859 Pourahmad, J., O'Brien, P., 2001. Biological reactive intermediates that mediate chromium (VI) toxicity. *Adv. Exp. Med. Biol.* 500, 203–207.

1860

1861 Pourahmad, J., Mihajlovic, A., O'Brien, P., 2001. Hepatocyte lysis induced by environmental metal toxins may involve apoptotic death signals initiated by mitochondrial injury. *Adv. Exp. Med. Biol.* 500, 249–252.

1862

1863 Pourahmad, J., Rabiei, M., Jokar, F., O'Brien, P., 2005. A comparison of hepatocyte cytotoxic mechanisms for chromate and arsenite. *Toxicology* 206, 449–460.

1864

1865 Pritchard, D., Singh, J., Carlisle, D., Patierno, S., 2000. Cyclosporin A inhibits chromium (VI)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells. *Carcinogenesis* 21, 2027–2033.

1866

1867 Pritchard, D., Ceryak, S., Ha, L., Fornasaglio, J., Hartman, S., O'Brien, T., Patierno, S., 2002. Mechanism of apoptosis and determination of cellular fate in chromium(VI)-exposed populations of telomerase-immortalized human fibroblasts. *Cell Growth Differ.* 12, 487–496.

1868

1869 Priya, S., Sudhakaran, P., 2008. Curcumin-induced recovery from hepatic injury involves induction of apoptosis of activated hepatic stellate cells. *Indian J. Biochem. Biophys.* 45, 317–325.

1870

1871 Qian, J., Zhai, X., Niu, M., Zhou, Q., Zhou, Y., 2012. Curcumin inhibits iron overload-induced hepatocytic apoptosis and nuclear factor- κ B activity. *Chin. Med. J. (Engl.)* 92, 1997–2001.

1872

1873 Quinteros, F., Machiavelli, L., Miler, E., Cabilla, J., Duvilanski, B., 2008. Mechanisms of chromium (VI)-induced apoptosis in anterior pituitary cells. *Toxicology* 249, 109–115.

1874

1875 Raganathan, N., Busi, F., Pluvinage, B., Sanfins, E., Dupret, J., Rodrigues-Lima, F., Dairou, J., 2010. The human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) is irreversibly inhibited by inorganic (Hg²⁺) and organic mercury (CH₃Hg⁺): mechanism and kinetics. *FEBS Lett.* 584, 3366–3369.

1876

1877 Rahman, S., Sultana, S., 2006. Chemopreventive activity of glycyrrhizin on lead acetate mediated hepatic oxidative stress and its hyperproliferative activity in Wistar rats. *Chem. Biol. Interact.* 160, 61–69.

1878

1879 Raja, N., Nair, B., 2008. Chromium(III) complexes inhibit transcription factors binding to DNA and associated gene expression. *Toxicology* 251, 61–65.

1880

1881 Rajakumar, D.V., Rao, M.N., 1994. Antioxidant properties of dehydrozingerone and curcumin in rat brain homogenates. *Mol. Cell. Biochem.* 140, 73–79.

1882

1883 Reddy, A.C., Lokesh, B.R., 1994. Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron. *Mol. Cell. Biochem.* 137, 1–8.

1884

1885 Reddy, M., Sasikala, P., Karthik, A., Sudheer, S., Murthy, L., 2012. Protective role of curcumin against arsenic trioxide toxicity during gestation and lactational periods. *Glob. Vet.* 9, 270–276.

1886

1887 Rennolds, J., Malireddy, S., Hassan, F., Tridandapani, S., Parinandi, N., Boyaka, P., Cormet-Boyaka, E., 2012. Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium. *Biochem. Biophys. Res. Commun.* 417, 256–261.

1888

1889 Rikans, L., Yamano, T., 2000. Mechanisms of cadmium-mediated acute hepatotoxicity. *J. Biochem. Mol. Toxicol.* 14, 110–117.

1890

1891 Ringman, J.M., Frautschi, S.A., Teng, E., Begum, A.N., Bardens, J., Beigi, M., Gyls, K.H., Badmaev, V., Heath, D.D., Apostolova, L.G., Porter, V., Vanek, Z., Marshall, G.A., Hellemann, G., Sugar, C., Masterman, D.L., Montine, T.J., Cummings, J.L., Cole, G.M., 2012. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. *Alzheimer's Res. Ther.* 4, 43.

1892

1893 Roshan, V.D., Assali, M., Moghaddam, A.H., Hosseinzadeh, M., Myers, J., 2011a. Exercise training and antioxidants: effects on rat heart tissue exposed to lead acetate. *Int. J. Toxicol.* 30, 190–196.

1894

1895 Roshan, V.D., Noredini, G., Hemmati, Y., 2011b. Effect of the curcumin supplementation on the regional bone mineral density of femur and tibial bones in young rats exposed to lead acetate. *Sci. Med. J.* 10, 295–307.

1896

1897 Roshan, V.D., Rahimi, M., Shirinbayan, V., Mahjoub, S., Hosseinzadeh, M., 2012. Effects of lead acetate, endurance training and curcumin supplementation on heat shock protein levels in liver tissue. *Int. J. Nutr. Metab.* 4, 114–120.

1898

1899 Roy, M., Sinha, D., Mukherjee, S., Paul, S., Bhattacharya, R.K., 2008. Protective effect of dietary phytochemicals against arsenite induced genotoxicity in mammalian V79 cells. *Indian J. Exp. Biol.* 46, 690–697.

1900

1901 Roy, M., Sinha, D., Mukherjee, S., Biswas, J., 2011. Curcumin prevents DNA damage and enhances the repair potential in a chronically arsenic-exposed human population in West Bengal, India. *Eur. J. Cancer Prev.* 20, 123–131.

1902

1903 Rubio, V., Valverde, M., Rojas, E., 2010. Effects of atmospheric pollutants on the Nrf2 survival pathway. *Environ. Sci. Pollut. Res. Int.* 17, 369–382.

1904

1905 Rudolf, E., Cervinka, M., Cerman, J., Schroterova, L., 2005. Hexavalent chromium disrupts the actin cytoskeleton and induces mitochondria-dependent apoptosis in human dermal fibroblasts. *Toxicol. In Vitro* 19, 713–723.

1906

1907 Ryberg, D., Alexander, J., 1984. Inhibitory action of hexavalent chromium (Cr(VI)) on the mitochondrial respiration and a possible coupling to the reduction of Cr(VI). *Biochem. Pharmacol.* 33, 2461–2466.

1908

1909 Ryberg, D., Alexander, J., 1990. Mechanisms of chromium toxicity in mitochondria. *Chem. Biol. Interact.* 75, 141–151.

1910

1911 Saeidnia, S., Abdollahi, M., 2013. Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century. *Toxicol. Appl. Pharmacol.* 271, 49–63.

1912

1913 Saïdi, S., Azaza, M., Windmolders, P., van Pelt, J., El-Feki, A., 2013. Cytotoxicity evaluation and antioxidant enzyme expression related to heavy metals found in tuna by-products meal: an in vitro study in human and rat liver cell lines. *Exp. Toxicol. Pathol.* 1–9.

1914

1915 Salama, A., El-Bahr, S., 2007. Effect of curcumin on cadmium-induced oxidative testicular damage in rats. *J. Med. Res. Inst.* 28, 167–173.

1916

1917 Sandhir, R., Gill, K.D., 1995. Effect of lead on lipid peroxidation in liver of rats. *Biol. Trace Elem. Res.* 48, 91–97.

1918

1919 Sangartit, W., Donpunha, W., Kukongviriyapa, U., Pakdeechote, P., Kukongviriyapan, V., Surawattananaw, P., 2012. Effect of curcumin on kidney function and arterial blood pressure in rats with long-term and low level exposure of lead and cadmium. *Srinagarind Med. J.* 27, 107–110.

1920

1921 Sankar, P., Gopal Telang, A., Kalaivanan, R., Karunakaran, V., Manikam, K., Sarkar, S.N., 2013a. Effects of nanoparticle-encapsulated curcumin on arsenic-induced liver toxicity in rats. *Environ. Toxicol.*

1922

1923 Sankar, P., Telang, A.G., Kalaivanan, R., Karunakaran, V., Suresh, S., Kesavan, M., 2013b. Oral nanoparticulate curcumin combating arsenic-induced oxidative damage in kidney and brain of rats. *Toxicol. Int. Health.*

1924

1925 Sankar, P., Telang, A.G., Suresh, S., Kesavan, M., Kannan, K., Kalaivanan, R., Sarkar, S., 2013c. Immunomodulatory effects of nanocurcumin in arsenic-exposed rats. *Int. Immunopharmacol.* 17, 65–70.

1926

1927 Sanmukhani, J., Satodia, V., Trivedi, J., Patel, T., Tiwari, D., Panchal, B., Goel, A., Tripathi, C.B., 2013. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. *Phytother. Res.*

- Santra, A., Das, G., De, B., Roy, B., Mazumder, D., 1999. Hepatic manifestations in chronic arsenic toxicity. *Indian J. Gastroenterol.* 18, 152–155.
- Santra, A., Chowdhury, A., Ghatak, S., Biswas, A., Dhal, G., 2007. Arsenic induces apoptosis in mouse liver is mitochondria dependent and is abrogated by N-acetylcysteine. *Toxicol. Appl. Pharmacol.* 220, 146–155.
- Sauer, J.M., Waalkes, M., Hooser, S., Kuester, R., McQueen, C., Sipes, I., 1997. Suppression of Kupffer cell function prevents cadmium induced hepatocellular necrosis in the male Sprague–Dawley rat. *Toxicology* 121, 155–164.
- Sehgal, A., Kumar, M., Jain, M., Dhawan, D.K., 2011. Combined effects of curcumin and piperine in ameliorating benzo(a)pyrene induced DNA damage. *Food Chem. Toxicol.* 49, 3002–3006.
- Selvam, C., Jachak, S.M., Thilagavathi, R., Chakraborty, A.K., 2005. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. *Bioorg. Med. Chem. Lett.* 15, 1793–1797.
- Sener, G., Sehirli, O., Tozan, A., Velioglu-Ovunc, A., Gedik, N., Omurtug, G.Z., 2007. Ginkgo biloba extract protects against mercury(II)-induced oxidative tissue damage in rats. *Food Chem. Toxicol.* 45, 543–550.
- Shah, B.H., Nawaz, Z., Pertani, S.A., Roomi, A., Mahmood, H., Saeed, S.A., Gilani, A.H., 1999. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca²⁺ signaling. *Biochem. Pharmacol.* 58, 1167–1172.
- Shaikh, Z., Vu, T., Zaman, K., 1999. Oxidative stress as a mechanism of chronic cadmium-induced hepatotoxicity and renal toxicity and protection by antioxidants. *Toxicol. Appl. Pharmacol.* 154, 256–263.
- Shalan, M.G., Mostafa, M.S., Hassouna, M.M., El-Nabi, S.E.H., El-Refaie, A., 2005. Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements. *Toxicology* 206, 1–15.
- Sharma, O.P., 1976. Antioxidant activity of curcumin and related compounds. *Biochem. Pharmacol.* 25, 1811–1812.
- Sharma, R., Gescher, A., Steward, W., 2005. Curcumin: the story so far. *Eur. J. Cancer* 41, 1955–1968.
- Shenker, B.J., Guo, T.L., O, I., Shapiro, I.M., 1999. Induction of apoptosis in human T-cells by methyl mercury: temporal relationship between mitochondrial dysfunction and loss of reductive reserve. *Toxicol. Appl. Pharmacol.* 157, 23–35.
- Shukla, P.K., Khanna, V.K., Khan, M.Y., Srimal, R.C., 2003. Protective effect of curcumin against lead neurotoxicity in rat. *Hum. Exp. Toxicol.* 22, 653–658.
- Singh, S., Vrishni, S., Singh, B.K., Rahman, I., Kakkar, P., 2010. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. *Free Radic. Res.* 44, 1267–1288.
- Singh, P., Mogra, P., Sankhla, V., Deora, K., 2011. Protective effects of curcumin on cadmium chloride induced colon toxicity in Swiss albino mice. *J. Cell. Mol. Biol.* 9, 31–36.
- Singh, P., Deora, K., Sankhla, V., Mogra, P., 2012. Curcumin rendered protection against cadmium chloride induced testicular damage in Swiss albino mice. *J. Cell. Mol. Biol.* 10, 31–38.
- Sinha, D., Biswas, J., Bishayee, A., 2013. Nrf2-mediated redox signaling in arsenic carcinogenesis: a review. *Arch. Toxicol.* 87, 383–396.
- Sokol, R., Twedt, D., McKim, J.J., Devereaux, M., Bacon, B., Britton, R., 1994. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. *Gastroenterology* 107, 1788–1798.
- Somparn, P., Phisalaphong, C., Nakornchai, S., Unchern, S., Morales, N.P., 2007. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. *Biol. Pharm. Bull.* 30, 74–78.
- Son, Y., Hitron, J., Wang, X., Chang, Q., Pan, J., Zhang, Z., Liu, J., Wang, S., Lee, J., Shi, X., 2010. Cr(VI) induces mitochondrial-mediated and caspase-dependent apoptosis through reactive oxygen species-mediated p53 activation in Jb6 Cl41 cells. *Toxicol. Appl. Pharmacol.* 245, 226–235.
- Soni, K.B., Kuttan, R., 1992. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. *Indian J. Physiol. Pharmacol.* 36, 273–275.
- Soudani, N., Bouaziz, H., Sefi, M., Chtourou, Y., Boudawara, T., Zeghal, N., 2013. Toxic effects of chromium (VI) by maternal ingestion on liver function of female rats and their suckling pups. *Environ. Toxicol.* 28, 11–20.
- Souza, V., Bucio, L., Jay, D., Chávez, E., Gutiérrez-Ruiz, M.C., 1996. Effect of cadmium on calcium transport in a human fetal hepatocytic cell line (WRL-68 cells). *Toxicology* 112, 97–104.
- Souza, V., Bucio, L., Gutiérrez-Ruiz, M., 1997. Cadmium uptake by a human hepatic cell line (WRL-68 cells). *Toxicology* 120, 215–220.
- Stacey, N.H., Kappus, H., 1982. Cellular toxicity and lipid peroxidation in response to mercury. *Toxicol. Appl. Pharmacol.* 63, 29–35.
- Stacey, N., Klaassen, C., 1981. Copper toxicity in isolated rat hepatocytes. *Toxicol. Appl. Pharmacol.* 58, 211–220.
- Stearns, D., Silveira, S., Wolf, K., Luke, A., 2002. Chromium(III) tris(picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribosyltransferase locus in Chinese hamster ovary cells. *Mutat. Res.* 513, 135–142.
- Stewart, D., Killeen, E., Naquin, R., Alam, S., Alam, J., 2003. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. *J. Biol. Chem.* 278, 2396–2402.
- Stohs, S., Bagchi, D., 1995. Oxidative mechanisms in the toxicity of metal ions. *Free Radic. Biol. Med.* 18, 321–336.
- Stummann, T., Hareng, L., Bremer, S., 2008. Embryotoxicity hazard assessment of cadmium and arsenic compounds using embryonic stem cells. *Toxicology* 252, 118–122.
- Subudhi, U., Das, K., Paital, B., Bhanja, S., Chainy, G., 2008. Alleviation of enhanced oxidative stress and oxygen consumption of L-thyroxine induced hyperthyroid rat liver mitochondria by vitamin E and curcumin. *Chem. Biol. Interact.* 173, 105–114.
- Surh, Y., 2003. Cancer chemoprevention with dietary phytochemicals. *Nat. Rev. Cancer* 3, 768–780.
- Tajbakhsh, S., Mohammadi, K., Deilami, I., Zandi, K., Ramedani, E., Asayesh, G., 2008. Antibacterial activity of indium curcumin and indium diacetylcurcumin. *Afr. J. Biotechnol.* 7, 3832–3835.
- Takaki, A., Jimi, S., Segawa, M., Hisano, S., Takebayashi, S., Iwasaki, H., 2004. Long-term cadmium exposure accelerates age-related mitochondrial changes in renal epithelial cells. *Toxicology* 203, 145–154.
- Tanikawa, K., Torimura, T., 2006. Studies on oxidative stress in liver diseases: important future trends in liver research. *Med. Mol. Morphol.* 39, 22–27.
- Tao, T.Y., Gitlin, J.D., 2003. Hepatic copper metabolism: insights from genetic disease. *Hepatology* 37, 1241–1247.
- Tapia, E., Soto, V., Ortiz-Vega, K., Zarco-Márquez, G., Molina-Jijón, E., Cristóbal-García, M., Santamaría, J., García-Niño, W., Correa, F., Zazueta, C., Pedraza-Chaverri, J., 2012. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. *Oxid. Med. Cell Longev.* 2012, 269039.
- Tapia, E., Zatarain-Barrón, Z., Hernández-Pando, R., Zarco-Márquez, G., Molina-Jijón, E., Cristóbal-García, M., Santamaría, J., Pedraza-Chaverri, J., 2013. Curcumin reverses glomerular hemodynamic alterations and oxidant stress in 5/6 nephrectomized rats. *Phytomedicine* 20, 359–366.
- Tarasub, N., Narula, K., Devakul Na Ayuthaya, W., 2008. Effects of curcumin on cadmium-induced hepatotoxicity in rats. *Thai. J. Toxicol.* 23, 100–107.
- Tarasub, N., Tarasub, C., Devakul, W., Ayuthaya, N., 2011. Protective role of curcumin on cadmium-induced nephrotoxicity in rats. *J. Environ. Chem. Ecotoxicol.* 3, 17–24.
- Tarasub, N., Junsecha, T., Tarasub, C., Devakul Na Ayuthaya, W., 2012. Protective effects of curcumin, vitamin C, or their combination on cadmium-induced hepatotoxicity. *J. Basic Clin. Pharm.* 3, 273–281.
- Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., La Ferla, B., Nicotra, F., Masserini, M., Antimisiaris, S.G., Gregori, M., Allsop, D., 2011. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's A β peptide. *Nanomed. Nanotechnol., Biol. Med.* 7, 541–550.
- Tayyem, R.F., Heath, D.D., Al-Delaimy, W.K., Rock, C.L., 2006. Curcumin content of turmeric and curry powders. *Nutr. Cancer* 55, 126–131.
- Thephinlap, C., Phisalaphong, C., Fucharoen, S., Porter, J.B., Srichairatanakool, S., 2009. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. *Med. Chem. (Los Angeles)* 5, 474–482.
- Thijssen, S., Cuypers, A., Maringwa, J., Smeets, K., Horemans, N., Lambrechts, I., Van Kerkhove, E., 2007. Low cadmium exposure triggers a biphasic oxidative stress response in mice kidneys. *Toxicology* 236, 29–41.
- Tisato, F., Marzano, C., Porchia, M., Pellei, M., Santini, C., 2010. Copper in diseases and treatments, and copper-based anticancer strategies. *Med. Res. Rev.* 30, 708–749.
- Tiwari, H., Rao, M.V., 2010. Curcumin supplementation protects from genotoxic effects of arsenic and fluoride. *Food Chem. Toxicol.* 48, 1234–1238.
- Topcu-Tarladaçalisir, Y., Akpolat, M., Uz, Y., Kizilay, G., Sapmaz-Metin, M., Cerkezflayabekir, A., Omurlu, I., 2013. Effects of curcumin on apoptosis and oxidoinflammatory regulation in a rat model of acetic acid-induced colitis: the roles of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. *J. Med. Food* 16, 296–305.
- Trujillo, J., Chirinio, Y., Molina-Jijón, E., Andérica-Romero, C., Tapia, E., P-C, J., 2013. Renoprotective effect of the antioxidant curcumin: recent findings. *Redox Biol.* 1, 448–456.
- Ueno, S., Susa, N., Furukawa, Y., Aikawa, K., Itagaki, I., 1989. Cellular injury and lipid peroxidation induced by hexavalent chromium in isolated rat hepatocytes. *Nihon Juigaku Zasshi* 51, 137–145.
- Ueno, S., Kashimoto, T., Susa, N., Furukawa, Y., Ishii, M., Yokoi, K., Yasuno, M., Sasaki, Y.F., Ueda, J., Nishimura, Y., Sugiyama, M., 2001. Detection of dichromate (VI)-induced DNA strand breaks and formation of paramagnetic chromium in multiple mouse organs. *Toxicol. Appl. Pharmacol.* 170, 56–62.
- Urbina-Cano, P., Bobadilla-Morales, L., Ramírez-Herrera, M.A., Corona-Rivera, J.R., Mendoza-Magaña, M.L., Troyo-Sanromán, R., Corona-Rivera, A., 2006. DNA damage in mouse lymphocytes exposed to curcumin and copper. *J. Appl. Genet.* 47, 377–382.
- Uruno, A., Motohashi, H., 2011. The Keap1-Nrf2 system as an in vivo sensor for electrophiles. *Nitric Oxide* 25, 153–160.
- Vajragupta, O., Boonchoong, P., Berliner, L., 2006. Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. *Free Radic. Res.* 38, 303–314.
- Valko, M., Morris, H., Cronin, M., 2005. Metals, toxicity and oxidative stress. *Curr. Med. Chem.* 12, 1161–1208.
- Valko, M., Rhodes, C.J., Moncol, J., Izakovic, M., Mazur, M., 2006. Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chem. Biol. Interact.* 160, 1–40.
- Valverde, M., Trejo, C., Rojas, E., 2001. Is the capacity of lead acetate and cadmium chloride to induce genotoxic damage due to direct DNA-metal interaction? *Mutagenesis* 16, 265–270.

2155 Vera-Ramirez, L., Pérez-Lopez, P., Varela-Lopez, A., Ramirez-Tortosa, M., Battino, M.,
2156 Quiles, J.L., 2013. Curcumin and liver disease. *BioFactors* 39, 88–100.

2157 Waalkes, M., Liu, J., Ward, J., Diwan, B., 2006. Enhanced urinary bladder and liver
2158 carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic
2159 and postnatal diethylstilbestrol or tamoxifen. *Toxicol. Appl. Pharmacol.* 215,
2160 295–305.

2161 Wan, X., Luo, X., 2007. Relationship between copper injury and apoptosis and the
2162 effect of curcumin on copper-injured BRL cells. *Chin. J. Contemp. Pediatr.* 9,
2163 567–570.

2164 Wan, X., Li, Y., Luo, X., 2007. Curcumin attenuated the lipid peroxidation and
2165 apoptotic liver injury in copper-overloaded rats. *Chin. J. Pediatr.* 45, 604–608.

2166 Wang, Y.J., Pan, M.H., Cheng, a L., Lin, L., Ho, YS., Hsieh, CY., Lin, JK., 1997. Stability of
2167 curcumin in buffer solutions and characterization of its degradation products. *J.*
2168 *Pharm. Biomed. Anal.* 15, 1867–1876.

2169 Wang, X., Xing, M., Shen, Y., Zhu, X., Xu, L., 2006. Oral administration of Cr(VI)
2170 induced oxidative stress, DNA damage and apoptotic cell death in mice.
2171 *Toxicology* 228, 16–23.

2172 Wang, X.-J., Sun, Z., Chen, W., Li, Y., Villeneuve, N.F., Zhang, D.D., 2008. Activation of
2173 Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151:
2174 enhanced Keap1-Cul3 interaction. *Toxicol. Appl. Pharmacol.* 230, 383–389.

2175 Wang, L., Shen, Y., Song, R., Sun, Y., Xu, J., Xu, Q., 2009. An anticancer effect of
2176 curcumin mediated by down-regulating phosphatase of regenerating liver-3
2177 expression on highly metastatic melanoma cells. *Mol. Pharmacol.* 76, 1238–
2178 1245.

2179 Wang, X.J., Hayes, J.D., Higgins, L.G., Wolf, C.R., Dinkova-Kostova, A.T., 2010.
2180 Activation of the NRF2 signaling pathway by copper-mediated redox cycling of
2181 para- and ortho-hydroquinones. *Chem. Biol.* 17, 75–85.

2182 Wang, L., Kou, M.-C., Weng, C.-Y., Hu, L.-W., Wang, Y.-J., Wu, M.-J., 2012. Arsenic
2183 modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth
2184 factor expression in endothelial cells: roles of ROS, NF-κB, and MAPK pathways.
2185 *Arch. Toxicol.* 86, 879–896.

2186 Wang, H., Xi, S., Liu, Z., Yang, Y., Zheng, Q., Wang, F., Xu, Y., Wang, Y., Zheng, Y., Sun,
2187 G., 2013a. Arsenic methylation metabolism and liver injury of acute
2188 promyelocytic leukemia patients undergoing arsenic trioxide treatment.
2189 *Environ. Toxicol.* 28, 267–275.

2190 Wang, Y., Fang, J., Huang, S., Chen, L., Fan, G., Wang, C., 2013b. The chronic effects of
2191 low lead level on the expressions of Nrf2 and Mrp1 of the testes in the rats.
2192 *Environ. Toxicol. Pharmacol.* 35, 109–116.

2193 Wataha, J.C., Lewis, J.B., McCloud, V.V., Shaw, M., Omata, Y., Lockwood, P.E., Messer,
2194 R.L.W., Hansen, J.M., 2008. Effect of mercury(II) on Nrf2, thioredoxin reductase-
2195 1 and thioredoxin-1 in human monocytes. *Dent. Mater.* 24, 765–772.

2196 Wielgus-Serafińska, E., Zawadzka, A., Falkus, B., 1980. The effect of lead acetate on
2197 rat liver mitochondria. *Acta Physiol. Pol.* 31, 659–668.

2198 Wongeakin, N., Sridulyakul, P., Jariyapongskul, A., Suksamrarn, A., Patumraj, S.,
2199 2009. Effects of curcumin and tetrahydrocurcumin on diabetes induced
2200 endothelial dysfunction. *Afr. J. Biochem. Res.* 3, 259–265.

2201 Wood, R., Mills, P.B., Knobel, G.J., Hurlow, W.E., Stokol, J.M., 1990. Acute dichromate
2202 poisoning after use of traditional purgatives: a report of 7 cases. *South Afr. Med.*
2203 *J.* 77, 640–642.

2204 Woźniak, F., Borzecki, Z., Swies, Z., 1991. Histopathologic and histochemical
2205 examination of rat liver after prolonged experimental application of
2206 potassium bichromate. *Ann. Univ. Mariae Curie-Skłodowska* 46, 65–68.

2207 Wright, J.S., 2002. Predicting the antioxidant activity of curcumin and
2208 curcuminoids. *J. Mol. Struct. THEOCHEM.* 591, 207–217.

2209 Wu, K.C., Liu, J.J., Klaassen, C.D., 2012. Nrf2 activation prevents cadmium-induced
2210 acute liver injury. *Toxicol. Appl. Pharmacol.* 263, 14–20.

2211 Xiao, F., Feng, X., Zeng, M., Guan, L., Hu, Q., Zhong, C., 2012. Hexavalent chromium
2212 induces energy metabolism disturbance and p53-dependent cell cycle arrest via
2213 reactive oxygen species in L-02 hepatocytes. *Mol. Cell. Biochem.* 371, 65–76.

2214 Xie, Y., Liu, J., Benbrahim-Tallaa, L., Ward, J., Logsdon, D., Diwan, B., Waalkes, M.,
2215 2007. Aberrant DNA methylation and gene expression in livers of newborn mice
2216 transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic.
2217 *Toxicology* 236, 7–15.

2218 Xu, S., Pi, H., Chen, Y., Zhang, N., Guo, P., Lu, Y., He, M., Xie, J., Zhong, M., Zhang, Y., Yu,
2219 Z., Zhou, Z., 2013a. Cadmium induced Drp1-dependent mitochondrial
2220 fragmentation by disturbing calcium homeostasis in its hepatotoxicity. *Cell*
2221 *Death Dis.* 4, 1–10.

2222 Xu, Z., Wang, Z., Li, J., Chen, C., Zhang, P., Dong, L., Chen, J., Chen, Q., Zhang, X., Wang,
2223 Z., 2013b. Protective effects of selenium on oxidative damage and oxidative
2224 stress related gene expression in rat liver under chronic poisoning of arsenic.
2225 *Food Chem. Toxicol.* 58C, 1–7.

2226 Yadav, R., Sankhwar, M., Shukla, R., Chandra, R., Pant, A., Islam, F., Khanna, V., 2009.
2227 Attenuation of arsenic neurotoxicity by curcumin in rats. *Toxicol. Appl.*
2228 *Pharmacol.* 240, 367–376.

2229 Yadav, R., Shukla, R., Sankhwar, M., Patel, D., Ansari, R., Pant, A., Islam, F., Khanna, V.,
2230 2010. Neuroprotective effect of curcumin in arsenic-induced neurotoxicity in
2231 rats. *Neurotoxicology* 31, 533–539.

2232 Yadav, R., Chandravanshi, L., Shukla, R., Sankhwar, M., Ansari, R., Shukla, P., Pant, A.,
2233 Khanna, V., 2011. Neuroprotective efficacy of curcumin in arsenic induced
2234 cholinergic dysfunctions in rats. *Neurotoxicology* 32, 760–768.

Yadav, A., Lomash, V., Samim, M., Flora, S., 2012a. Curcumin encapsulated in
chitosan nanoparticles: a novel strategy for the treatment of arsenic toxicity.
Chem. Biol. Interact. 199, 49–61.

Yadav, B., Taurin, S., Larsen, L., Rosengren, R.J., 2012b. RL71, a second-generation
curcumin analog, induces apoptosis and downregulates Akt in ER-negative
breast cancer cells. *Int. J. Oncol.* 41, 1119–1127.

Yamano, T., Kusanke, S.D., Rikans, L.E., 1999. Attenuation of cadmium-induced liver
injury in senescent male Fischer 344 rats: role of metallothionein and
glutathione. *Toxicol. Appl. Pharmacol.* 161, 225–230.

Yang, B., Fu, J., Zheng, H., Xue, P., Yarborough, K., Woods, C.G., Hou, Y., Zhang, Q.,
Andersen, M.E., Pi, J., 2012. Deficiency in the nuclear factor E2-related factor 2
renders pancreatic β-cells vulnerable to arsenic-induced cell damage. *Toxicol.*
Appl. Pharmacol. 264, 315–323.

Ye, J., Wang, S., Leonard, S., Sun, Y., Butterworth, L., Antonini, J., Ding, M.,
Rojanasakul, Y., Vallyathan, V., Castranova, V., Shi, X., 1999. Role of reactive
oxygen species and p53 in chromium(VI)-induced apoptosis. *J. Biol. Chem.* 274,
34974–34980.

Yee, S., Choi, B.H., 1996. Oxidative stress in neurotoxic effects of methylmercury
poisoning. *Neurotoxicology* 17, 17–26.

Yogosawa, S., Yamada, Y., Yasuda, S., Sun, Q., Takizawa, K., Sakai, T., 2012.
Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle
arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human
colon cancer cells. *J. Nat. Prod.* 75, 2088–2093.

Youns, M., Hoheisel, J.D., Efferth, T., 2010. Traditional Chinese medicines (TCMs) for
molecular targeted therapies of tumours. *Curr. Drug Discov. Technol.* 7, 37–45.

Yousef, M., El-Demerdash, F., Radwan, F., 2008. Sodium arsenite induced
biochemical perturbations in rats: ameliorating effect of curcumin. *Food*
Chem. Toxicol. 46, 3506–3511.

Youssef, D., Nichols, C.E., Cameron, T.S., Balzarini, J., De Clercq, E., Jha, A., 2007.
Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues.
Bioorg. Med. Chem. Lett. 17, 5624–5629.

Yu, R., Mandekar, S., Lei, W., Fahl, W.E., Tan, T., N. KA., 2000. P38 mitogen-activated
protein kinase negatively regulates the induction of phase II drug-metabolizing
enzymes that detoxify carcinogens. *J. Biol. Chem.* 275, 2322–2327.

Yu, S., Zheng, W., Xin, N., Chi, Z., Wang, N., Nie, Y., Feng, W., Wang, Z., 2010.
Curcumin prevents dopaminergic neuronal death through inhibition of the c-
Jun N-terminal kinase pathway. *Rejuvenation Res.* 13, 55–64.

Yuan, Y., Jiang, C., Xu, H., Sun, Y., Hu, F., Bian, J., Liu, X., Gu, J., Liu, Z., 2013. Cadmium-
induced apoptosis in primary rat cerebral cortical neurons culture is mediated
by a calcium signaling pathway. *PLoS One* 8, e64330.

Yuann, J., Liu, K., Hamilton, J., Wetterhahn, K., 1999. In vivo effects of ascorbate and
glutathione on the uptake of chromium, formation of chromium(V), chromium-
DNA binding and 8-hydroxy-2'-deoxyguanosine in liver and kidney of
osteogenic disorder shionogi rats following treatment with chromium(VI).
Carcinogenesis 20, 1267–1275.

Zahir, F., Rizvi, S.J., Haq, S.K., Khan, R.H., 2006. Effect of methyl mercury induced free
radical stress on nucleic acids and protein: implications on cognitive and motor
functions. *Indian J. Clin. Biochem.* 21, 149–152.

Zaman, G.J., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude
Elferink, R.P., Baas, F., Borst, P., 1995. Role of glutathione in the export of
compounds from cells by the multidrug-resistance-associated protein. *Proc.*
Natl. Acad. Sci. USA 92, 7690–7694.

Zhang, S., Chen, S., Li, W., Guo, X., Zhao, P., Xu, J., Chen, Y., Pan, Q., Liu, X., Zychlinski,
D., Lu, H., Tortorella, M., Schambach, A., Wang, Y., Pei, D., Esteban, M., 2011.
Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease
induced pluripotent stem cells using gene therapy or the chaperone drug
curcumin. *Hum. Mol. Genet.* 20, 3176–3187.

Zhang, W., Feng, H., Gao, Y., Sun, L., Wang, J., Li, Y., Wang, C., Zhao, L., Hu, X., Sun, H.,
Sun, D., 2013. Role of pigment epithelium-derived factor (PEDF) in arsenic-
induced cell apoptosis of liver and brain in a rat model. *Biol. Trace Elem. Res.*
151, 269–276.

Zhao, X., Jiang, T., Wang, L., Yang, H., Zhang, S., Zhou, P., 2010. Interaction of
curcumin with Zn(II) and Cu(II) ions based on experiment and theoretical
calculation. *J. Mol. Struct.* 984, 316–325.

Zhao, R., Hou, Y., Xue, P., Woods, C.G., Fu, J., Feng, B., Guan, D., Sun, G., Chan, J.Y.,
Waalkes, M.P., Andersen, M.E., Pi, J., 2011. Long isoforms of NRF1 contribute to
arsenic-induced antioxidant response in human keratinocytes. *Environ. Health*
Perspect. 119, 56–62.

Zhao, R., Yang, B., Wang, L., Xue, P., Deng, B., Zhang, G., Jiang, S., Zhang, M., Liu, M., Pi,
J., Guan, D., 2013. Curcumin protects human keratinocytes against inorganic
arsenite-induced acute cytotoxicity through an NRF2-dependent mechanism.
Oxid. Med. Cell Longev. 2013, 412576.

Zheng, S., Yumei, F., Chen, A., 2007. De novo synthesis of glutathione is a
prerequisite for curcumin to inhibit hepatic stellate cell (HSC) activation. *Free*
Radic. Biol. Med. 43, 444–453.

Ziemacki, G., Viviano, G., Merli, F., 1989. Heavy metals: sources and environmental
presence. *Ann. Ist Super Sanita* 25, 531–536.

Q8